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Glycan recognition by lectins initiates clinically relevant processes such as toxin binding or tumor
spread. Thus, the development of potent inhibitors has a medical perspective. Toward this goal, we
report the synthesis of both rigid and flexible bivalent lactosides on scaffolds that include secondaryand
tertiary terephthalamides and N,N0-diglucosylterephthalamides. Construction of these compounds
involved Schmidt-Michel glycosidation, and amide coupling or Ugi reactions of relevant glycosyl
amines in key steps. A glycocluster based on a rigid glycophane was also prepared from coupling of a
glucuronic acid derivative and p-xylylenediamine with subsequent ring-closing metathesis. Finally, a
more flexible bivalent lactoside was produced from lactosyl azide with use of the copper-catalyzed
azide-alkyne cycloaddition. Distances between lactose residues were analyzed computationally as
were their orientations for the relatively rigid subset of compounds. Distinct spacing properties were
revealed by varying the structure of the scaffold or by varying the location of the lactose residue on the
scaffold. To relate these features to bioactivity a plant toxin and human adhesion/growth-regulatory
galectins were used as sensors in three types of assay, i.e. measuring agglutination of erythrocytes,
binding toglycans of a surface-immobilized glycoprotein, or binding to humancells.Methodologically,
the commonhemeagglutination assaywas found to be considerably less sensitive thanboth solid-phase
and cell assays. The bivalent compounds were less effective at interfering with glycoprotein binding to
the plant toxin than to human lectins. Significantly, a constrained compound was identified that
displayed selectivity in its inhibitory potency between galectin-3 and its proteolytically processed form.
Conversely, compounds with a high degree of flexibility showed notable ability to protect human cells
fromplant toxin binding. The applied conjugation chemistry thus is compatible with the long-term aim
to produce potent and selective lectin inhibitors.
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Introduction
Carbohydrates have ideal properties to generate an un-
rivalled number of oligomers. They are capable of engaging
in molecular recognition events in biological systems, under-
lying the concept of the sugar code.1 Indeed, glycan chains
presented on cell surface glycoconjugates are versatile bio-
chemical signals by serving as direct contact sites for recep-
tors (lectins) that bind to carbohydrates (trans-interactions)
and as potent molecular switches regulating aspects of
protein accessibility and functionality (cis-interactions).1,2
Besides the structure of the headgroup of a glycan chain its
presentation and local density govern the affinity in inter-
molecular interactions, as recently revealed in the case of
physiological core substitutions in N-glycans which trigger
significant alterations in glycan conformations and, impor-
tantly, in lectin affinity.3 Distinct changes in glycan display
including microdomain formation in natural systems can
thus lead to induction of cellular responses such as anoikis/
apoptosis or autoimmune suppression via lectin binding.4 To
underscore the emerging clinical relevance a tumor suppres-
sor and responses in inflammation can apparently work
on this level by remodelling cell surface glycan profiles and
even lectin expression to result in host defense/antima-
lignancy effects.4c,d Clinically disadvantageous, lectin bind-
ing to glycans is also involved in disease progression.
Herewith, it gives an incentive for drug design. Considering
the multiple, medically relevant activities of cell surface
glycans in concert with lectins in regulating, for example,
adhesion, migration, proliferation, or tissue invasion or
serving as docking sites for plant/bacterial toxins,1 it clearly
is an attractive goal to develop new molecules which can
efficiently interfere with binding of certain effectors to cell
surface glycans.
Of current interest to us toward this goal is a series of
bivalent glycoclusters of varying degree of scaffold flexibil-
ity, altering ligand spacing with a view to profiling the
structure-bioactivity relationships. As a first step, we re-
cently described the synthesis and biological evaluation of a
series of bivalent mannosides based on terephthalamide and
glycocyclophane scaffolds, the latter being derived from
phenylene-1,4-diamines.5 Initial testing for bioactivity with
leguminous lectins in cell-based assays showed that presen-
tation of the mannose residues on a rigid macrocyclic scaf-
fold can lead to enhanced inhibitory capacity.5 Evidently, the
mannose moieties maintained ligand-binding capacity for
the tested plant lectins. Thus, this proof-of-principle result
encourages further efforts with a headgroup different from
that of mannose and medically relevant lectins.
Due to its positioning at branch ends of glycan chains and
frequent involvement in lectin binding β-galactose satisfies the
requirement for biological relevance.1,2 Testing of bivalent
scaffolds presenting β-galactosides (e.g., lactosides) in assays
with a biohazardous toxin and with human lectins was there-
fore envisaged to provide amedical perspective. Consequently,
we were interested to establish synthetic routes that would
allow bivalent lactosides based on macrocyclic and terephtha-
lamide scaffolds to be generated. As follows, the syntheses of
ligands (Chart 1) with β-lactose conjugated to terephthala-
mide scaffolds6 (1-2), N0,N0-diglucosylterephthalamides
(3-5), and a rigid macrocyclic glycocyclophane 8 are
presented. Preparations of 6 and 7 with increased flexibility
compared to the conformationally arrested compound 8 are
included as was the generation of the triazole derivative 9.
Geometrical aspects of presentation of the β-lactose units in
the more rigid compounds were then comparatively inferred
by computational methods.
Bioactivity of the sugar headgroup and the impact of struc-
tural properties were next examined in the commonly used
hemeagglutination test and also in a solid-phase binding assay.
The latter assay was based on evaluating the ability of synthetic
compounds to inhibit binding of lectins to a natural glycopro-
tein (asialofetuin (ASF) with threeN-glycosylation sites prefer-
entially occupied by complex-type triantennary N-glycans).
Since any clinical application would be based on impairing
lectin binding to cells, we also determined the extent of lectin
binding tonativehumancells as a functionof thepresenceof the
new compounds. Lectin selection for the assays was based on
the aim to protect cells from toxicity, in addition to evaluating
the potential of the test panel to interfere with progression of
disease in malignancy due to activity of distinct adhesion/
growth-regulatory galectins.7 In detail, the binding of Viscum
album agglutinin (VAA) and human galectins-3 and -4 to the
surface-presented glycoprotein was monitored in the absence/
presence of a test compound, using free lactose as an internal
standard of inhibitory potency. Galectin-3 has two special
features in this respect: it can pentamerize in the presence of a
(1) Gabius, H.-J., Ed. The Sugar Code. Fundamentals of glycosciences;
Wiley-VCH: Weinheim, Germany, 2009.
(2) (a) Sharon, N.; Lis, H. InGlycosciences: Status and Perspectives; Gabius,
H.-J., Gabius, S., Eds.; Chapman & Hall: London, UK, 1997; pp 133-162. (b)
von der Lieth, C.-W.; Siebert, H.-C.; Kozar, T.; Burchert, M.; Frank, M.; Gilleron,
M.; Kaltner, H.; Kayser, G.; Tajkhorshid, E.; Bovin, N. V.; Vliegenthart, J. F. G.;
Gabius, H.-J. Acta Anat. (Basel) 1998, 161, 91–109. (c) Gabius, H.-J.; Siebert,
H.-C.; Andre, S.; Jimenez-Barbero, J.; R€udiger, H. ChemBioChem 2004, 5, 740–
764. (d) Gabius, H.-J. Crit. Rev. Immunol. 2006, 26, 43–79. (e) Gabius, H.-J.
Biochem. Soc. Trans. 2008, 36, 1491–1496. (f) Andre, S.; Kozar, T.; Kojima, S.;
Unverzagt, C.; Gabius, H.-J. Biol. Chem. 2009, 390, 557–566. (g) Honke K.;
Taniguchi, N. InThe Sugar Code. Fundamentals of glycosciences; Gabius, H.-J.,
Ed.; Wiley-VCH: Weinheim, Germany, 2009; pp 385-401. (h) Ledeen, R. W.;
Wu, G. In The Sugar Code. Fundamentals of glycosciences; Gabius, H.-J., Ed.;
Wiley-VCH: Weinheim, Germany, 2009; pp 495-516. (i) Zuber, C.; Roth, J. In
The Sugar Code. Fundamentals of glycosciences; Gabius, H.-J., Ed.; Wiley-
VCH: Weinheim, Germany, 2009; pp 87-110.
(3) (a) Andre, S.; Unverzagt, C.; Kojima, S.; Dong, X.; Fink, C.; Kayser,
K.; Gabius, H.-J. Bioconjugate Chem. 1997, 8, 845–855. (b) Unverzagt, C.;
Andre, S.; Seifert, J.; Kojima, S.; Fink, C.; Srikrishna, G.; Freeze, H. H.;
Kayser, K.; Gabius, H.-J. J. Med. Chem. 2002, 45, 478–491. (c) Andre, S.;
Unverzagt, C.; Kojima, S.; Frank, M.; Seifert, J.; Fink, C.; Kayser, K.; von
der Lieth, C.-W.; Gabius, H.-J. Eur. J. Biochem. 2004, 217, 118–134. (d)
Andre, S.; Kozar, T.; Schuberth, R.; Unverzagt, C.; Kojima, S.; Gabius, H.-
J. Biochemistry 2007, 46, 6984–6995.
(4) (a) Kopitz, J.; von Reitzenstein, C.; Andre, S.; Kaltner, H.; Uhl, J.;
Ehemann, V.; Cantz, M.; Gabius, H.-J. J. Biol. Chem. 2001, 276, 35917–
35923. (b) Rappl, G.; Abken, H.; Muche, J. M.; Sterry, W.; Tilgen, W.;
Andre, S.; Kaltner, H.; Ugurel, S.; Gabius, H.-J.; Reinhold, U. Leukemia
2002, 16, 840–845. (c) Andre, S.; Sanchez-Ruderisch, H.; Nakagawa, H.;
Buchholz, M.; Kopitz, J.; Forberich, P.; Kemmner, W.; B€ock, C.; Deguchi,
K.; Detjen, K. M.; Wiedenmann, B.; von Knebel Doeberitz, M.; Gress, T.
M.; Nishimura, S.-I.; Rosewicz, S.; Gabius, H.-J. FEBS J. 2007, 274, 3233–
3256. (d)Marathe,D.D.; Chandrasekaran, E. V.; Lau, J. T.Y.;Matta,K. L.;
Neelamegham, S. FASEB J. 2008, 22, 4154–4167. (e) Patsos, G.; Andre, S.;
Roeckel, N.; Gromes, R.; Gebert, J.; Kopitz, J.; Gabius, H.-J. Glycobiology
2009, 19, 726–734. (f) Schwartz-Albiez, R. InThe SugarCode. Fundamentals of
glycosciences; Gabius, H.-J., Ed.; Wiley-VCH: Weinheim, Germany, 2009; pp
447-467. (g) Wang, J.; Lu, Z.-H.; Gabius, H.-J.; Rohowsky-Kochan, C.; Ledeen,
R. W.; Wu, G. J. Immunol. 2009, 182, 4036–4045.
(5) Andre, S.; Velasco-Torrijos, T.; Leyden, R.; Gouin, S.; Tosin, M.;
Murphy, P. V.; Gabius, H.-J. Org. Biomol. Chem. 2009, 7, 4715–4725.
(6) (a) Avalos, M.; Babiano, R.; Carretero, M. J.; Cintas, P.; Higes, F. J.;
Jimenez, J. L.; Palacios, J. C. Tetrahedron 1998, 54, 615–628. (b) Murphy, P.
V.; Bradley, H.; Tosin, M.; Pitt, N.; Fitzpatrick, G. M.; Glass, W. K. J. Org.
Chem. 2003, 68, 5692–5704. (c) Tosin, M.; Gouin, S. G.; Murphy, P. V.Org.
Lett. 2005, 7, 211–214. (d) Bradley, H.; Fitzpatrick, G.; Glass, W. K.; Kunz,
H.; Murphy, P. V. Org. Lett. 2001, 3, 2629.
9012 J. Org. Chem. Vol. 74, No. 23, 2009
JOCArticle Leyden et al.
multivalent ligand and it is physiologically truncated by matrix
metalloproteinases-2/-9 to yield a trimmed (truncated) version
with diminishedpropensity for oligomer formation.8Galectin-3
and its truncated derivative were thus tested to reveal any
difference in sensitivity to the glycocompounds and a selective
inhibitor was identified. The obtained results demonstrate the
bioactivity of this panel of glycoclusters as well as reveal a
notable influenceof assay system, compound, lectin, andmatrix
properties on inhibitory potency.
Results and Discussion
Synthesis of Glycoclusters. Synthetic routes were first es-
tablished to produce 1-9. It was envisaged that 1 and 2 could
be prepared from lactosyl amine 10. Fittingly, coupling of 10
with terephthaloyl chloride in the presence of triethyla-
mine and subsequent Zemplen deacetylation gave 1. Since
the glycosyl amine 10 also contained a small amount of the
R-anomer, a mixture of diamides was obtained from the
coupling reaction. The bivalent compounds 11 and a lesser
amount of 12 containing R-glycosyl amides were thus also
obtained after HPLC-based separation of the deacetylated
diamide mixture (Scheme 1). Next, the Ugi reaction of 10 in
the presence of formaldehyde, methyl isocyanoacetate, and
terephthalic acid and subsequent Zemplen deacetylation re-
sulted in the bivalent compound 2. It differs from 1 in that
tertiary amides are present as opposed to secondary amides.
In the next step, approaches to bivalent lactosides based
on N,N0-diglucopyranosylterephthalamide scaffolds were
studied. The Schmidt-Michel glycoside coupling reaction
of trichloroacetimidate 14 with 13 with TMSOTf as catalyst
and subsequent reaction of the trisaccharide product with
SnCl4 and TMSN3 generated azide 15. Catalytic hydrogena-
tion led to the glycosyl amine and subsequent coupling with
terephthaloyl chloride followed by deacetylation as before
gave 3 where the lactosyl units are attached to both 6-O
atoms of the scaffold (Scheme 2).
CHART 1. β-Lactose-Based Glycoclusters
(7) (a) Gabius, H.-J. Biochimie 2001, 83, 659–666. (b) Gabius, H.-J.;
Darro, F.; Remmelink, M.; Andre, S.; Kopitz, J.; Danguy, A.; Gabius, S.;
Salmon, I.;Kiss, R.Cancer Invest. 2001, 19, 114–126. (c)Nagy,N.; Legendre,
H.; Engels, O.; Andre, S.; Kaltner, H.; Wasano, K.; Zick, Y.; Pector, J.-C.;
Decaestecker, C.; Gabius, H.-J.; Salmon, I.; Kiss, R. Cancer 2003, 97, 1849–
1858. (d) Lahm, H.; Andre, S.; Hoeflich, A.; Kaltner, H.; Siebert, H.-C.;
Sordat, B.; von der Lieth, C.-W.; Wolf, E.; Gabius, H.-J. Glycoconj. J. 2004,
20, 227–238. (e) Delacour, D.; Gouyer, V.; Zanetta, J.-P.; Drobecq, H.;
Leteurtre, E.; Grard, G.; Moreau-Hannedouche, O.; Maess, E.; Pons, A.;
Andre, S.; Le Bivic, A.; Gabius, H.-J.;Manninen,A.; Simons, K.; Huet, G. J.
Cell Biol. 2005, 169, 491–501. (f) Jimenez, M.; Saiz, J. L.; Andre, S.; Gabius,
H.-J.; Solı´s, D.Glycobiology 2005, 15, 1386–1395. (g) Jimenez,M.; Andre, S.;
Siebert, H.-C.; Gabius, H.-J.; Solı´s, D. Glycobiology 2006, 16, 926–937. (h)
Villalobo, A.; Nogales-Gonzales, A.; Gabius, H.-J. Trends Glysci. Glyco-
technol. 2006, 18, 1–37. (i) Langbein, S.; Brade, J.; Badawi, J. K.; Hatzinger,
M.; Kaltner, H.; Lensch, M.; Specht, K.; Andre, S.; Brinck, U.; Alken, P.;
Gabius, H.-J.Histopathology 2007, 51, 681–690. (j)Moisa, A.; Fritz, P.; Eck,
A.; Wehner, H.-D.; M€urdter, T.; Simon, W.; Gabius, H.-J. Anticancer Res.
2007, 27, 2131–2140. (k) Andre, S.; Sansone, F.; Kaltner, H.; Casnati, A.;
Kopitz, J.; Gabius, H.-J.; Ungaro, R. ChemBioChem 2008, 9, 1649–1661. (l)
Saussez, S.; Decaestecker, C.; Mahillon, V.; Cludts, S.; Cappouillez, A.;
Chevalier, D.; Kaltner, H.; Andre, S.; Toubeau, G.; Leroy, X.; Gabius, H.-J.
Laryngoscope 2008, 118, 1583–1590. (m) Cada, Z.; Smetana, K., Jr.; Lacina,
L.; Plzakova, Z.; Stork, J.; Kaltner, H.; Russwurm, R.; Lensch, M.; Andre,
S.; Gabius, H.-J. Folia Biol (Praha) 2009, 55, 145–52. (n) Stechly, L.;Morelle,
W.; Dessein, A.-F.; Andre, S.; Grard, G.; Trinel, D.; Dejonghe, H.-J.;
Leteurtre, E.; Drobecq, H.; Trugnan, G.; Gabius, H.-J.; Huet, G. Traffic
2009, 10, 438–450.
(8) (a) Herrmann, J.; Turck, C. W.; Atchison, R. E.; Huflejt, M. E.;
Poulter, L.; Gitt, M. A.; Burlingame, A. L.; Barondes, S. H.; Leffler, H. J.
Biol. Chem. 1993, 268, 26704–26711. (b) Ahmad, N.; Gabius, H.-J.; Andre,
S.; Kaltner, H.; Sabesan, S.; Roy, R.; Liu, B.; Macaluso, F.; Brewer, C. F. J.
Biol. Chem. 2004, 279, 10841–10847. (c) Dam, T. K.; Gabius, H.-J.; Andre,
S.; Kaltner, H.; Lensch, M.; Brewer, C. F. Biochemistry 2005, 44, 12564–
12571. (d) K€ubler, D.; Hung, D.-W.; Dam, T. K.; Kopitz, J.; Andre, S.;
Kaltner, H.; Lohr, M.; Manning, J. C.; He, L.; Wang, H.; Middelberg, A.;
Brewer, C. F.; Reed, J.; Lehmann, W.-D.; Gabius, H.-J. Biochim. Biophys.
Acta 2008, 1780, 716–722.
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The synthesis of 4 was achieved via the glucopyrano-
side 16. Glycosidation of the acetylated lactosyl trichlo-
roacetimidate donor 14 opened the way to the desired
trisaccharide 17. Acetolysis gave the glycosyl acetate deriva-
tive and its subsequent reaction with azidotrimethylsilane
in the presence of SnCl4 the desired β-azide 18. Reaction
of 18 as described for 15 produced bivalent compound 4
(Scheme 3). The lactose units are covalently linked to the
two 4-O atoms of the N,N0-diglucosylterephthalamide
scaffold.
To prepare other analogues which would be available by
using the 3-O atoms of the scaffold as an attachment site, a
respective strategy was developed. Toward this aim, glyco-
sidation reactions of the glycosyl acceptor 20 with donor 14
were not successful, which contrasted with what we observed
for the other acceptors (Schemes 2 and 3). An orthoester
byproduct, often detected in glycosidation reactions, was
obtained instead of the desired glycosidic product. To ad-
dress this problem the benzoylated lactosyl trichloroaceti-
midate 19was prepared and its reactionwith 20 investigated,
leading to the successful formation of the desired β-glycoside
21 in good yield. Hydrolysis of the acetonide groups, sub-
sequent acetylation followed by reaction of the product with
SnCl4 and TMSN3, and then catalytic hydrogenation gave
the amine 22. Treatment of amine 22 with terephthaloyl
chloride as before and ensuing removal of the acyl protecting
groups resulted in 5 (Scheme 4).
With this series of bivalent lactosides in hand we next
added compounds to the panel based on scaffolds that were
amides of glucuronic acid. Consequently, the acceptor 23,
which we had used previously to prepare mannosides, on
reaction with acetylated lactose donor 14 gave the undesired
orthoester 24. Application of the benzoylated donor 19 in the
glycosidation yielded the suitable trisaccharide intermediate,
which was then converted to 25 after selective removal of the
allyl ester with Pd(0) catalysis (Scheme 5).9 In our previous
work we had synthesized the bivalent mannosides via cou-
pling of a glucuronic acid derivative with phenylene-1,4-
diamine. The products of coupling of phenylene-1,4-diamine
to the acid 25 were analyzed indicating that only one
SCHEME 1. Synthesis of 1, 2, and 11
SCHEME 2. Synthesis of 3
(9) Kunz, H.; Waldmann, H. Angew. Chem., Int. Ed. 1984, 23, 71–72.
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trisaccharide residue had been added to one amine group
(Scheme 5). It is presumed that formation of the first amide
group leads to a reduction in nucleophilicity of the second
amine group of the phenylene-1,4-diamine residue preclud-
ing formation of a second amide. We thus investigated the
preparation of diamides from 1,4-di(aminomethyl)benzene
(p-xylylenediamine), where electron-withdrawing effects
were expected to have been lessened. Conversion of 25
to its acid chloride with a view to using this for the
amide synthesis led to the formation of the glycosyl chlo-
ride 26, tentatively explained by the mechanistic proposal
outlined in Scheme 6. The activation ofO-glycosidic linkages
by manipulation of remote carboxylic acid groups has
already been delineated and favorably utilized in glyco-
sidation reactions.10 Herein, a glycosyl carbenium ion is
proposed to be generated via the acid chloride, the for-
mer which is subsequently trapped by chloride ion
(Scheme 6). Eventually, the desired coupling reaction en
route to the diamide was achieved by activation of the acid
25 with HOBt, DIPEA, and HATU in the presence of the
p-xylylenediamine. Removal of the acetate and benzoate
protecting groups gave the flexible divalent compound 6
(Scheme 5).
Having established conditions for the formation of 6, we
next worked toward the synthesis of bivalent lactosides
based on a glycocyclophane scaffold derived from the p-
xylylenediamine. The acceptor 28 was therefore prepared
from 27 as described previously5 and its reaction with 19 and
subsequent chemoselective deallylation with Pd(0) gave 29.
Reaction of 29 with p-xylylenediamine in the presence of
HOBt, HATU, andDIPEA generated the protected divalent
compound 30 (Scheme 7), a suitable precursor for ring
closure metathesis (RCM).
SCHEME 3. Synthesis of 4
SCHEME 4. Synthesis of 5
(10) Kim, K. S.; Kim, J. H.; Yong, Lee, J.; Lee, Y. J.; Park, J. J. Am.
Chem. Soc. 2001, 123, 8477–8481.
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The subsequent RCM of 30 with the Grubbs-I catalyst
gave a mixture of macrocyclic isomers containing E- and
Z-alkene groups, and unreacted 30 was also recovered.
Hydrogenation of the mixture produced 31 and 32. These
compounds were readily separated by chromatography. The
removal of the protecting groups from 31 and 32was the last
step of the route providing the acyclic derivative 7 and the
rigid macrocyclic derivative 8 (Scheme 8).
Finally, the bivalent lactoside 9was prepared from 34 and
the lactosyl azide 33with the copper-catalyzed azide-alkyne
cycloaddition reaction.11 To facilitate purification of 9,
the product from the click reaction was acetylated, puri-
fied by chromatography, and subsequently deacetylated
(Scheme 9). Having herewith completed the synthetic part,
we next proceeded to calculate geometrical aspects of ligand
positioning in the bivalent systems.
Analysis of Ligand Spacing. The use of rigid scaffolds
presenting ligands can avoid entropic penalties that occur
upon binding to a receptor, particularly if they are preorga-
nized into a constellation favorable for binding. If the two
sugar headgroups react with different lectin molecules,
then orientation and spacing may also have a bearing on
bioactivity. The aim to relate structure to function ex-
plains our interest to calculate interligand spatial relation-
ships for the bivalent lactosides. At the outset, the panel
of compounds was separated into two categories based on
their relative flexibility. Twoparameterswere chosen todefine
the interligand spacing: the distances between the twoGlcC-1
atoms of the lactose residues was defined as the interlactose
distance whereas the torsion Gal C4-Glc C1-Glc C1-Gal
C4 corresponding to the lactose residues was defined as the
lactose orientation (see Figure 2D). Since the β-lactosides 1-5
and 8 were judged to have fewer degrees of freedom when
compared to 6, 7, and 9, conformational analysis was focused
on the former structures. When calculating the spatial rela-
tionships between the two lactose residues in compounds
1-5 and 8, we used Macromodel for model building and
all subsequent computations.12 Experimentally observed
SCHEME 5. Synthesis of 6 SCHEME 6. Proposed Route of Formation of 26
SCHEME 7. Synthesis of 30
(11) (a) Kolb, H. C.; Finn,M.G.; Sharpless, K. B.Angew. Chem., Int. Ed.
2001, 40, 2004–2021. (b) Meldal, M.; Tornoe, C. W. Chem. Rev. 2008, 108,
2952–3015. (c) Leyden, R.; Murphy, P. V. Synlett 2009, 1949–1950.
(12) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.;
Lipton,M.; Caufield, C.; Chang,G.; Hendrickson, T.; Still,W.C. J. Comput.
Chem. 1990, 11, 440–467.
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glycosidic torsion angles (φ = O5-C1-O1-Cx; ψ =
C1-O1-Cx-C(xþ1); ω=O5-C5-C6-O1) were used to
guide the building13 of model structures establishing the
structure from which conformational searching commenced.
In detail, the glycosidic torsions from a published crystal
structure of a β-lactoside14 (φ=-88; ψ=-161) defined the
corresponding torsions in the lactose residues of the model
structures. To complete themodels of 3-5 additional torsions
for the glycosidic linkage between the glucose residue of the
scaffold and the glucose residue of the lactose needed to be
defined; the φ, ψ, and ω values were again obtained from X-
ray crystal structural data. For the β-D-Glc(1-6)-β-D-Glc
linkage in 3 the φ, ψ, and ω were -59, -155, and -61,
respectively;15 for the β-D-Glc(1-4)-β-D-Glc linkage in 4, the
φ andψusedwere-76 and132;16 for theβ-D-Glc(1-3)-β-D-
Glc linkage in 4, the φ and ψ used were -94 and 78.17
Equally relevant studies on the structural orientations of
N-glycosyl benzamides had been carried out previously,
providing a basis to define the preferred torsional parameters
SCHEME 8. Synthesis of 7 and 8
SCHEME 9. Synthesis of 9
(14) Qingfeng, P.; Noll, B. C.; Serianni, A. S.Acta Cryst. C 2005, 61, 674–
677.
(15) Arene, F.; Newman, A.; Longchambon, F. C. R. Acad. Sci. 1979,
288, 331–334.
(16) Chu, S. S.; Jeffrey, G. A. Acta Cryst. B 1968, 24, 830–8.
(17) Noguchi, K.; Okyama, K.; Kitamura, S.; Takeo, K.Carbohydr. Res.
1992, 237, 33–42.
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for glycosyl amide residues of 1-5. Thus N-glycosyl benza-
mides that contain secondary amides adopt the Z-configura-
tion (or trans amide), whereas those that are tertiary amides
prefer the E-configuration (cis amide). The glycosyl amide
torsion defined by H1-C1-N-Hwas constrained at a value
of 171 (anti-conformation); this is close to the average of
FIGURE 1. The ten lowest energy structures for 1, 3, and 8 generated by conformational searchwithMacromodel are superimposed. For 1 and
3 structures were obtained where the terephthalamide torsion was cis or trans and these are shown separately.
FIGURE 2. Structural profiles of low-energy conformational isomers of 1-5 and 8 (A-C) and definition of parameters (D). Data for 2 were
obtained from stochastic molecular dynamics simulations for the isomer where the two carbonyl groups of the terephthalamide residue were trans.
Data for other compoundswas obtained from low-energy structures within 12 kJ/mol ofminimumobtained by systematic conformational searches.
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the angles observed (168.2 to 175.0) in a number of X-ray
crystal structures of related secondary glycosyl amides and
supported by 1H NMR (JH1-NH≈ 9.0 Hz) in solution.18 The
two carbonyl groups of the terephthalamide residues were
constructed with a trans coplanar arrangement (dihedral
defined by OdC;CdO 180 ( 60) for 1 and 3-5. During
modelingof 2, the aromatic groupswere not coplanarwith the
carbonyl groups for reasons discussed previously.6 All these
parameters combined facilitated the establishment of the
initial models of 1-5. A starting structure of the glycocyclo-
phane derivative 8 was also established and together with the
models of 1, 2, and 3-5 was used to start systematic con-
formational searches; for 1 and 2 stochastic molecular dy-
namics was also explored. The AMBER (assisted model
building with energy refinement) force field and the GB/SA
continuum for water in Macromodel were generally applied.
For the conformational searches all isomers within 12 kJ/mol
of the global minimum were retained and used in the subse-
quent analysis. The terephthalamides containing secondary
amides (1, 3-5) consistently gave low-energy structureswhere
the carbonyl groups of the terephthalamides were either cis or
trans (shown for low-energy structures of 1 and 3 in Figure 1).
This torsion, defined byOdC;CdOatoms of the terephtha-
lamide residue, is referred to as the terephthalamide torsion
subsequently. Our analysis (Figure 2A,C) for all the low-
energy structures generated showed how the terephtalamide
torsion affected interlactose distance and lactose orientation.
For 1 the interlactose distance was constrained between 10.1
and 10.4 A˚ for all low-energy structures. Increased flexibility
was observed for 3 where interlactose distance ranged from
13.0 to 18.8 A˚, whereas intermediate flexibility was observed
for 4 (19.1-20.7 A˚) and 5 (16.3-17.2 and 18.0-18.4 A˚). In all
low-energy conformers of 8 (Figure 1), which was the most
rigid structure, the glucuronic acid residues inherent in the
macrocycle adopted a cis relationship (or a U-shape) with
respect to the benzene residue, as was also found in related
macrocycles derived from phenylene-1,4-diamine. The inter-
lactose distance was firmly constrained between 15.4 and
15.5 A˚ in 8. Conformational searches on 2 led to highly folded
low-energy structures which were deemed unlikely to be
accessed by lectins and which possibly were artifacts. Thus,
a stochastic molecular dynamics simulation instead explored
the conformational space for 2 and commenced from a
structure where the carbonyl groups of the terephthalamide
residue were trans (OdC;CdO torsion∼90). In the molec-
ular dynamics runs a temperature of 300K, time step of 1.5 fs,
equilibration time of 1.0 ps, and simulation time of 2 ns were
set and 500 structures were sampled over the duration of the
simulation. The result derived from the sampled structures is
also included in Figure 2. The interlactose distance was found
to be constrained between 7.2 and 8.1 A˚ for 2. Similar
stochastic molecular dynamics simulations were also per-
formed for 1 (not shown), coming upwith reasonable correla-
tions between the interlactose distances and lactose
orientations of structures generated in the dynamics simula-
tions and in conformational searching.
In addition, plots were generated for each set of confor-
mers showing the relationship between interlactose distance
and lactose orientation (Figure 2B), which further demon-
strated the unique spatial profile for each molecule. This
analysis was also useful to depict the constraints imposed on
each of the molecules. For example, for 5 there are two low-
energy clusters: the first corresponds to a set of conformers
with a lactose orientation that varies from-50 to-22 and
a corresponding interlactose distance of 16.3-17.2 A˚; the
second cluster is a set of conformers where the lactose
orientation varies between 84 and 139 and a corresponding
interlactose distance of 18.0-18.4 A˚. In general, the analysis
shows that, while the subset of glycoclusters can adopt a
range of interlactose distances (∼7-21 A˚) as well as a very
large range of interlactose orientations from-180 toþ180,
not all regions of space definable by both these parameters
are occupied. Running a similar conformational search for
the triazole derivative 9 indicated that it should be more
flexible than the selected rigid subset. For 9 the interlactose
distance was shown to vary from 9 to 17 A˚ and the lactose
orientation varied between -165 and þ 165, suggesting it
can have spacing arrangements not accessible to 1-5 and 8.
This would be the case also for 6 and 7. If bioactive, it will
thus be a key question whether flexible compounds such as 6
and 9 or less flexible substances will exhibit relatively higher
potency for interfering with lectin activity. Having prepared
the panel of glycoclusters and examined their conforma-
tional properties, the next step was therefore to ascertain the
implied bioactivity of the carbohydrate headgroups and, if
possible, to establish structure-activity profiles for inhibi-
tory lectin binding.
Inhibition Studies. At the outset, we performed hemeag-
glutination tests classical to lectin research.1 Using trypsin-
treated, glutaraldehyde-fixed rabbit erythrocytes, the activ-
ity of lactose or the glycoclusters was assessed for their ability
to inhibit lectin-mediated hemeagglutination in a total vo-
lume of 50 μL. Lactose (but not controls such as mannose)
was effective at blocking lectin activity at concentrations of 2
and 0.8 mM, respectively, when using the plant toxin (25 ng/
50 μL) and galectin-3 (2 μg/50 μL). The sugar units in
compound 9 matched the activity of free lactose but no
inhibitory activity was seen for any other test substance up
to a concentration of 25 mM (given as sugar concentration).
To infer whether the setting of this assay, where cell agglu-
tination was themeasured parameter, may have a bearing on
sensitivity to pick up compound activity, we next employed
an assay that measured the ability of a glycocluster to inhibit
binding, in this case to a surface-immobilized glycoprotein.
In the solid-phase setting, the extent of the lectin-glycopro-
tein interaction and inhibition thereof are determined spec-
trophotometrically.
To set up optimal conditions for this assay the coating
density and lectin concentration were systematically tested
until the dependence of signal intensity on lectin concentra-
tion was in the linear range. The signal was shown to be
consistently dependent on the protein-carbohydrate inter-
action, as revealed by haptenic inhibition with lactose.
Under these subsaturating conditions, the sensitivity to
determine inhibitory potency of the synthetic compounds
was optimal. As seen in Figure 3, glycoclusters from the
synthetic panel blocked lectin binding to the glycans of the
glycoprotein with higher efficiency than free lactose. Ob-
viously, the conjugation chemistry did not impair the bio-
activity, and attachment to a scaffold could enhance the
(18) Rawe, S. L.; Doyle, D.; Zaric, V.; Rozas, I.; McMahon, K.; Tosin,
M.; Mueller Bunz, H.; Murphy, E. P.; O’ Boyle, K. M.; Murphy, P. V.
Carbohydr. Res. 2006, 341, 1370–1390.
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inhibitory potency of lactose. Titrations were used to deter-
mine the concentration required to reach 50% inhibition
(IC50; Table 1). The inhibitory effects weremost pronounced
for the proteolytically truncated form of human galectin-3
and for galectin-4, when using ASF as matrix. The minimal
interlactose distance observed for compound 2 translated
into potent inhibition in these two cases. In comparison, the
plant toxin (VAA), where the two readily accessible lectin
sites of the 2γ subdomains are separated by 87 A˚,7g showed
no notable response to cluster formation or scaffold rigidi-
fication. Even more important, the unprocessed form of
galectin-3 was much less sensitive to the presence of 2. Thus,
inhibitory capacity depended on the type of lectin and scaffold
used to present the lactose aswell as lectin-site presentation (e.
g., galectin-3 vs. truncated galectin-3). Itmight also dependon
matrix properties. To address this issue the solid-phase assay
was carried out with a glycoprotein with only one N-glycosy-
lation site, this strictly bearing bi- instead of triantennary N-
glycans, i.e. serum amyloid P component (SAP). The effect of
using SAP as the matrix was thus to reduce the glycan
microdensity. In this case, enhancements of inhibitory activity
were measured for galectin-3, with all compounds being at
least 5-fold more active than free lactose and substances 4-9
being the most potent reaching up to a 50-fold activity
increase. In contrast, toxin binding remained less susceptible.
Considering this aspect and attaining increased physiological
relevance, we next probed binding of the plant toxin and
galectin-3 to the surface of native cells, in this case human B-
lymphoblastoid Croco II cells. Interference by the glycoclus-
ters was quantified.
All measurements were routinely performed with aliquots
of the same cell batch and passage, prolonged culture periods
with inevitable impact on cell features were hereby avoided.
The extent of carbohydrate-dependent cell binding was
experimentally determined by fluorescent staining in FACS-
can analysis, obtaining the percentage of positive cells and
signal intensity on a logarithmic scale as read-out, as pre-
sented in Figure 4. The binding of the labeled lectin to the cell
surface shifted the curve representing the staining profile of
each lectin-exposed cell population from the position of the
control (given as the shaded area in each figure), and the
presence of an effective inhibitorwillmove the curve back into
the direction of the control. Optimal conditions with a sub-
saturating lectin concentration and a lactose concentration in
the linear range of signal intensity were identified first by
systematic testing (Figure 4A,B). Routinely, measurements
were done in triplicateswith up to three independent series.As
exemplarily illustrated in Figure 4C-F, compounds 6 and 9
were considerablymore active than free lactose to block plant
toxin binding to the cells, which correlated reasonably well
with the binding data obtained from the solid-phase assay. In
the case of galectin-3, the measurements (scans not shown)
came up with a broadly similar trend as observed in the solid-
phase assay, and 8was less potent than 6 and 9 in this setting.
In detail, five compounds superseded the activity of free
lactose. With standard deviations of less than 11%, the
difference between the flexible and rigid compounds 6 and 8
seen in solid-phase assays remained with respective values of
34.8vs. 39.8 relative to49.9 for lactose inmean intensity (at 0.5
mM sugar concentration), whereas compounds 2 and 3 were
less potent than lactose with intensity values of 51.8 and 61.6.
Compound 9 also resulted in marked inhibition to 35.1 in
intensity. Thus, the substances 6 and 9 are particularly
effective to reduce lectin association to this type of native
human cells. Flexibility of bivalent compounds thus appears
to be a favorable factor when aiming to inhibit the toxin and
galectin-3.
Summary and Conclusions
We have reported the synthesis of different types of
bivalent lactosides based on terephthalamides and glyco-
cyclophanes as well as other analogues. Rather rigid
FIGURE 3. Inhibition of binding of biotinylated human galectin-3 (A) and human galectin-4 (B) to the glycans of surface-immobilized
asialofetuin by lactose (b) and the lactose-presenting compounds 2 (O), 6 (Δ), and 8 (0) (see Table 1 for IC50 values). The inhibitor
concentration given is normalized to lactose for direct comparison. Assays were routinely done in triplicates for up to five independent series
with standard deviations not exceeding 17%.
TABLE 1. IC50 Values (mM per lactose residue) for Blocking Binding
of Lectins to Surface-Immobilized ASF
compd
lactose
units per
molecule
VAAa
[0.5 μg
mL-1]
galectin-3
[5 μg
mL-1]
galectin-3
(truncated)
[30 μg mL-1]
galectin-4
[5 μg
mL-1]
1 2 0.7 1.85 0.15 0.3
2 2 1.4 1.6 0.06 0.08
3 2 1.3 2.1 0.15 1.1
4 2 0.9 0.7 0.6 0.12
5 2 0.8 1.8 0.15 0.3
6 2 0.3 0.6 0.15 0.12
7 2 0.9 1.4 5 0.3
8 2 1.2 1.6 0.3 1.1
9 2 0.4 1.2 0.15 0.15
11 2 1.0 1.8 0.08 0.15
lactose 1 0.7 2.7 0.6 2.5
aViscum album agglutinin/toxin.
9020 J. Org. Chem. Vol. 74, No. 23, 2009
JOCArticle Leyden et al.
compoundswere characterized computationallywith respect
to geometry of presentation of the sugar headgroups. Bioac-
tivity of the glycocompounds was systematically tested in
hemeagglutination as well as solid-phase and cell assays.
Haemagglutination as a test system proved rather insensi-
tive, where only one compound was found to be active as
inhibitor of lectin-dependent erythrocyte agglutination. In
contrast, measuring the extent of lectin binding to glycopro-
teins on a solid phase or on cell surfaces as the experimental
end point disclosed remarkable bioactivity. These experi-
ments added substantial support to the concept that both
terephthalamide and glycocyclophanes19 can be considered
as suitable scaffolds for presentation of carbohydrate li-
gands.20,21 Either introducing structural changes to a scaf-
fold (e.g., compare 1, 2, and 8) or strategically grafting a
lactose residue to different locations of a common scaffold
(compare 3-5) led to diverse interlactose spacing. These
changes in geometry can apparently factor into the observed
alterations for inhibitory capacity, especially for the trun-
cated form of galectin-3 and the tandem-repeat-type galectin
(galectin-4). In addition, increasing rigidity of a scaffold by
macrocyclisation (6 and 7< 8) also affects lectin reactivity to
bivalent scaffolds, with a trend toward activity loss in assays
with the plant toxin as compounds become more rigid.
Protection of cells from association with the plant toxin
was best achieved with the flexible compound 6, in accord
with the data from solid-phase assays. The relatively in-
creased activity for the flexible derivatives could be due to
their ability to access favorable ligand spacings not possible
for the more rigid compounds. In addition, the chemical
characteristics of the spacer and its environment may also
play a role in enhancing binding properties, as does the
choice of glycoprotein used as matrix and the cell surface,
rendering it difficult to draw unambiguous a priori con-
clusions.
The structural analysis indicates that it is unlikely that
compounds exert their inhibition by binding to multiple
carbohydrate recognition sites on one lectin as would be
the case, for example, for the glycoside cluster effect of
triantennary N-glycans homing in on the hepatic asialogly-
coprotein receptor; it seemsmore likely that the effects would
be due to bivalent compounds binding to more than one
lectin molecule, possibly promoting lectin clustering. At any
rate, the sugar headgroups maintained bioactivity after
conjugation and attained differential reactivity to the tested
human lectins, as seen especially for compound 2 and the
truncated form of galectin-3 and galectin-4 with a more than
10-fold and even higher increase of sugar activity relative to
free lactose. This gain in activity seen in solid-phase assays
could be due to constraint of the lactose residues into a
favorable presentation at minimal interlactose distance, a
benefit of using a scaffold based on the tertiary terephthala-
mide. The differential activity of 2 between galectin-3 and its
naturally derived truncated form illustrates the potential to
exploit physiological changes in binding-site presentation of
a lectin for selective inhibition. Synthesis of a bivalent
structure 11 incorporating an R-lactosyl amide linkage led
to notable activity against the two galectins noted above but
FIGURE 4. Illustration of binding of labeled plant toxin to cells of
the human B-lymphoblastoid line Croco II as a function of lectin
concentration (A), of the presence of lactose as haptenic inhibitor
(B), and of the compounds at a fixed concentration of 2 mM lactose
per assay (C-F). Controls in the absence of lectin and in the absence
of inhibitor are given by the shaded area and the solid black line.
Quantitative data on the percentage of positive cells and mean
fluorescence intensity are listed in each panel. Lectin concentrations
at 0.05, 0.1, 0.2, 0.5, and 1 μg/mL resulting in signals of increasing
level (A); assays at 0.4 μg/mL lectin with increasing concentrations
of lactose at 1, 2, 4, 20, and 40 mM document corresponding
decreases of level of signal (B). Using a constant concentration of
2 mM normalized to the sugar content the panel of test substances
was assayed: compounds 2 (thin gray line), 1 (dashed black line),
and 4 (black line) in panel C where data for positive and negative
controls are listed as bold numbers, compounds 3 (dashed black
line), 5 (thin gray line), and 6 (black line) in panel D, compounds 8
(dashed black line) and 9 (thin gray line) in panel E, and compounds
7 (dashed black line) and 11 (thin gray line) in panel F.
(19) For applications of both cyclic peptides and cyclophanes as scaffolds
for multivalent ligand display see: (a) Hayashida, O.; Hamachi, I. J. Org.
Chem. 2004, 69, 3509–3516. (b) Wittmann, V.; Seeberger, S. Angew. Chem.,
Int. Ed. 2000, 39, 4348–4352. (c) Ohta, T.; Miura, N.; Funitani, N.;
Nakajima, F.; Niikura, K.; Sadamoto, R.; Guo, C.-T.; Suzuki, T.; Suzuki,
Y.; Yasuo,M.;Monde, K.; Nishimura, S.-I.Angew. Chem., Int. Ed. 2003, 42,
5186–5189.
(20) Hirschmann, R. Angew. Chem., Int. Ed. 1991, 30, 1278.
(21) The application of carbohydrates and carbohydrate-derived struc-
tures as scaffolds for presentation of recognition groups in chemical biology
and medicinal chemistry has recently been reviewed. (a) Yamazaki, N.;
Kojima, S.; Bovin, N. V.; Andre, S.; Gabius, S.; Gabius, H.-J. Adv. Drug
Delivery Rev. 2000, 43, 225–244. (b) Murphy, P. V.; O’ Brien, J. L.; Gorey-
Feret, L. J.; Smith, A. B., III Bioorg. Med. Chem. Lett. 2002, 12, 1763–66. (c)
Meutermans, W.; Le, G. T.; Becker, B. ChemMedChem 2006, 1, 1164–1194.
(d)Murphy, P. V.;Dunne, J. L.Curr. Org. Synth. 2006, 3, 403–437. (e) Velter,
I.; La Ferla, B.; Nicotra, F. J. Carbohydr. Chem. 2006, 25, 97–138. (f)
Murphy, P. V. Eur. J. Org. Chem. 2007, 4177–4187. (g) Murphy P. V.;
Velasco-Torrijos, T. In Glycoscience-Chemistry and Chemical Biology, 2nd
ed.;. Fraser-Reid, B., Tatsuta, K., Thiem, J., Eds.; Springer-Verlag: Berlin-
Heidelberg, Germany, 2008; p 997. (h) Chabre, Y. M.; Roy, R. In The Sugar
Code. Fundamentals of glycosciences; Gabius, H.-J.,Ed.; Wiley-VCH: Wein-
heim, Germany, 2009; pp 53-70.
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not the plant toxin. In sum, the conjugation chemistry is
compatible with the long-term aim to develop inhibitors with
selectivity to certain members among a family of medically
relevant human lectins. Inhibitory efficiency was obtained
with bivalent compounds, offering the perspective to in-
crease ligand density. Also of note for further work, fine-
specificity differences between homologous lectins could be
exploited by respective tailoring of the structure of the
headgroup, hereby reducing cross-reactivity.
Experimental Section
N,N0-Di(β-D-galactopyranosyl-(1f4)-β-D-glucopyranosyl)tere-
phthalamide 1 andN-(β-D-Galactopyranosyl-(1f4)-β-D-glucopy-
ranosyl)-N0-(β-D-galactopyranosyl-(1f4)-R-D-glucopyranosyl)te-
rephthalamide 11. The lactosyl amine 1022 (0.473 g, 0.744 mmol)
and DIPEA (0.16 mL, 0.967 mmol) in dry THF (10 mL) were
added dropwise at rt into freshly recrystallized terephthaloyl
chloride (68 mg, 0.335 mmol) in dry THF. After 2 h the
solvent was removed and chromatography of the residue
(EtOAc-cyclohexane, gradient elution, 1:1 to 3:2 to 2:1) gave
a mixture of diamides as a white amorphous solid (0.432 g,
92%). Deacetylation of the diamide mixture (0.187 g, 0.133
mmol) gave a 79:20:1 mixture of 1, 11, and 12 (0.108 g,
quantitative yield). Semipreparative HPLC (isocratic elution
with water-CH3CN, 99:1, flow rate 10 mL/min) was used to
separate 1, 11, and 12. Analytical data for 1: [R]D þ58.7 (c 0.7,
H2O);
1H NMR (500 MHz, D2O, 30 C) δ 7.94 (s, 4H), 5.24 (d,
J=9.2 Hz, 2H), 4.48 (d, J=7.8 Hz, 2H), 3.96 (d, J=12.0 Hz,
2H), 3.93 (d, J=3.3Hz, 2H), 3.85 (dd, J=12.3Hz, J=2.3Hz,
2H), 3.83-3.71 (m, 12H), 3.67 (dd, J = 10.0 Hz, J = 3.4 Hz,
2H), 3.62 (t, J=9.0 Hz, 2H), 3.57 (dd, J=9.9 Hz, J=7.9 Hz,
2H); 13C NMR (125 MHz, D2O) δ 171.2 (CONH), 136.8 (C),
128.2 (CH), 103.1, 80.0, 78.0, 76.8, 75.6, 75.4, 72.8, 71.7, 71.2,
68.8 (each CH), 61.3, 60.1 (each CH2); IR (KBr) 3481-3259 (br
signal), 1657, 1545, 1383, 1298, 1082, 1041 cm-1; HRMS (ESI)
found 811.2609 [M-H]-, C32H47N2O22 requires 811.2620, and
found 835.2626 [MþNa]þ, C32H48N2NaO22 requires 835.2596.
Analytical data for 11: [R]Dþ42.6 (c 0.96, H2O); 1H NMR (500
MHz, D2O, 25 C) δ 7.93 (2 d, J= 8.4 Hz, 2H), 5.83 (d, J=4.6
Hz, 1H), 5.27 (d, J=9.2 Hz, 1H), 4.51 (dd, J=7.8 Hz, J=4.1
Hz, 1H), 4.00 (br s, 1H), 3.98 (br s, 1H), 3.96 (s, 1H), 3.89 (s, 2H),
3.86-3.73 (m, 6H), 3.72-3.68 (m, 1H), 3.66 (t, J= 9.0 Hz, 1H),
3.59 (dt, J = 10.4 Hz, J = 7.9 Hz, 1H); 13C NMR (125 MHz,
D2O) δ 172.0, 170.9 (each CO), 136.9, 136.2 (each C), 128.0,
127.8, 102.8, 79.7, 77.1, 78.0, 77.7, 76.5, 75.3, 75.1, 72.5, 71.7,
71.6, 71.4, 70.9, 69.2, 68.5 (each CH), 61.0, 59.8 (each CH2);
HRMS (ESI) found 835.2635 [M þ Na]þ, C32H48N2NaO22
requires 835.2596.
N,N0-Di(β-D-galactopyranosyl-β-(1f4)-β-D-glucopyranose)-
N,N0-di[(1-methoxycarbonyl)methylamino-2-oxoethyl]terephthala-
mide 2.Terephthalic acid (73mg, 0.44mmol), amine 10 (0.558 g,
0.878 mmol), and formaldehyde (80 μL of a 37% soln,
1.023 mmol) were suspended inMeOH (13mL) and the mixture
was stirred at rt for 1 h. Methyl isocyanoacetate (80 μL, 0.878
mmol) was then added and the mixture was stirred at rt for 18 h.
The reaction was then heated to 45 C for 6 h and then cooled to
rt and left to stir for a further 18 h and then solvent was removed
under diminished pressure. Chromatography of the residue
(gradient elution, EtOAc to EtOAc-MeOH, 98:2), obtained
after removal of solvent, gave the protected intermediate as a
white amorphous solid (0.352 g, 48%). Zemplen deacetylation
of this intermediate (0.352 g, 0.212 mmol) gave a yellow powder
(0.222 g, 98%) that was purified further by semipreparative
HPLC to give 2 as an interconverting mixture (83:38) of EE and
EZ isomers;6 [R]Dþ18 (c 1.22, H2O); 1HNMR (600MHz, D2O,
30 C) data for EE isomer: δ 7.70 (s, 4H), 4.85 (d, J = 8.9 Hz,
2H), 4.42 (d, J=7.7Hz, 2H), 4.37 (d, J=14.5Hz, 4H), 4.12 (d,
4H), 3.97 (dd, J=12.5Hz, J= 1.5Hz, 2H), 3.90 (d, J=3.1Hz,
2H), 3.83-3.72 (m, 10H), 3.73-3.62 (m, 10H), 3.57-3.47 (m,
6H); selected 1HNMRdata for the EZ isomer: δ 7.67 (d, J= 6.0
Hz, 2H), 7.61 (d, J=5.9Hz, 2H), 5.77 (d, J=9.2Hz, 2H,H-1),
4.48 (d, J=7.7 Hz, 2H, H-10); 13C NMR (125MHz, D2O) data
for EE isomer: δ 174.4, 172.2 (CO2Me, CONH), 136.1 (C),
127.9, 103.1, 87.5, 77.8, 73.0, 75.6, 74.3, 72.7, 71.1, 70.1, 68.8
(each CH), 61.3, 60.3 (each CH2), 53.1 (CH3), 45.0, 41.6 (each
CH2); IR (KBr) 3456-3305 (br s), 1743, 1655, 1444, 1383, 1225,
1078 cm-1; LRMS (ESI) 1069.5 [M - H]-, 1093.1 [M þ Na]þ;
HRMS (ESI) found 1069.3503 [M-H]-, C42H61N4O28 requires
1069.3472.
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-(1f4)-2,3,6-tri-
O-acetyl-β-D-glucopyranosyl-(1f6)- 2,3,4-tri-O-acetyl-1-azido-
1-deoxy-β-D-glucopyranose 15. Trichloroacetamide 1423 (65 mg,
84 μmol), acceptor 13 (29.2 mg, 84 μmol),24 and molecular sieves
4 A˚ (166 mg) were dried at high vacuum for 2 h. Dry dichlor-
omethane was then added (2 mL) and the solution was stirred for
2 h at rt. TMSOTf (1.54 μL, 8.4 μmol) was added and the mixture
was stirred for 30min at rt. SatdNaHCO3was then added and the
stirring continued for a further 30 min. The mixture was then
filtered through Celite, washing with dichloromethane (5 mL).
The solvent was removed and chromatography of the residue
(EtOAc-cyclohexane, 3:2) gave a protected trisaccharide inter-
mediate (42 mg, 52%) as a white powder. This protected trisac-
charide (0.966 g, 1 mmol) was dissolved in dry CH2Cl2 (20 mL)
under N2. Azidotrimethylsilane (340 μL, 2.5 mmol,) and tin(IV)
chloride (60 μL, 0.5mmol) were added and themixturewas stirred
for 15 min. Solid NaHCO3 (0.5 g) was then added and stirring
continued for an additional 30min. The reactionmixturewas then
diluted with dichloromethane (20 mL), washed with satd NaH-
CO3 (2 mL) and water (30 mL), dried (MgSO4), and filtered, then
the solvent was removed under vacuum. Chromatography of the
residue (cyclohexane-EtOAc, 4:6) afforded 15 as a white solid
(0.78 g, 82%); mp 104 C; [R]20D -12 (c 0.5, CHCl3); 1H NMR
(300MHz, CDCl3) δ (ppm) 5.35 (d, J=3.9 Hz, 1H), 5.19 (t, J=
9.3 Hz, 1H), 5.19 (t, J= 9.0 Hz, 1H), 5.11 (dd, J= 7.8 Hz, J=
10.2 Hz, 1H), 4.96 (dd, J=10.2 Hz, J=3.3 Hz, 1H), 4.94-4.86
(m, 4H), 4.63 (d, J=9.0 Hz, 1H), 4.55-4.48 (m, 3H), 4.15-4.05
(m, 3H), 3.90-3.73 (m, 4H), 3.80 (t, J= 9.3 Hz, 1H), 3.63-3.56
(m, 2H), 3.52 (dd, J=10.8 Hz, J=6.0 Hz, 1H), 2.15, 2.13, 2.10,
2.07, 2.06, 2.05 (2s), 2.03, 2.00, 1.97 (each s); 13C NMR (75MHz,
CDCl3) δ (ppm) 170.4, 170.3, 170.2, 170.0, 169.5, 169.3, 169.2
(each CO), 101.2, 100.6 (each CH), 87.8 (CH), 76.2, 75.4,
72.9, 72.7, 71.5, 71.1, 71.0, 69.2, 68.6 (each CH), 68.1 (CH2),
66.7 (CH), 61.9, 60.9 (each CH2), 20.9, 20.7, 20.6 (each CH3);
HRMS (ESI) found 972.2709 [M þ Naþ], C38H51N3NaO25
requires 972.2709.
N,N0-Di(β-D-galactopyranosyl-(1f4)-O-β-D-glucopyrano-
syl-(1f6)-β-D-glucopyranosyl)terephtalamide 3. Catalytic hy-
drogenation of the azide 15 (0.102 g, 0.105 mmol) gave the
desired glycosyl amine intermediate as a white solid (96 mg,
99%). Reaction of this amine (0.132 g, 0.143 mmol) with
terephthaloyl chloride (11 mg, 0.0715 mmol) as described for
10 gave, after chromatography (cyclohexane-EtOAc, 1:4 to
1:3), the protected diamide (0.114 g, 40%). Deacetylation (0.1 g,
0.57 mmol) gave 3 as a white powder (quantitative yield); [R]20D
þ2 (c 0.2, H2O); 1H NMR (300 MHz, CDCl3) δ (ppm) 7.96
(s, 4H), 5.25 (d, J= 8.4 Hz, 2H), 4.55 (d, J= 8.1 Hz, 2H), 4.45
(22) (a) Peto, C.; Batta, G.; Gy€orgydeak, Z.; Sztaricskai, F., Liebigs Ann.
Chem. 1991, 5, 505-507. (b) Aravind, S.; Park, W. K. C.; Brochu, S.; Roy, R.
Tetrahedron Lett. 1994, 35, 7739–7742.
(23) Li, H.; Cai, M.-S.; Li, Z.-J. Carbohydr. Res. 2000, 328, 611–615.
(24) Lee, G. S.; Lee, Y.-J.; Choi, S. Y.; Park, Y. S.; Yoon, K. B. J. Am.
Chem. Soc. 2000, 122, 12151–12157.
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(d, J = 7.8 Hz, 2H), 4.25 (d, J = 10.5 Hz, 2H), 3.37-4.00 (m,
32H); 13C NMR (100 MHz, CDCl3) δ (ppm) 173.7 (CO), 139.3
(C), 130.8, 105.8, 105.2, 82.8, 81.3, 79.5, 79.3, 78.2, 77.6, 77.1,
75.6, 75.4, 74.5, 73.8 (each CH), 72.1 (CH2), 71.4 (CH), 63.8,
62.9 (CH2); HRMS (ESI) found 1159.3596 [M þ Hþ], C44H68-
N2NaO32 requires 1159.3653.
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-(1f4)-2,3,6-tri-
O-acetyl-β-D-glucopyranosyl-(1f4)-2,3,6-tri-O-benzoyl-1-O-
methyl-r-D-glucopyranose 17. Glycosidation coupling of 16
with 14 as described for 13 gave, after chromatography
(EtOAc-cyclohexane, 35:75 to 40:60), 17 (48%); mp 121
C; [R]20D þ51 (c 0.5, CH2Cl2); 1H NMR (300 MHz, CDCl3)
δ (ppm) 8.08 (d, J = 7.2 Hz, 2H), 8.00 (d, J = 7.5 Hz, 2H),
7.93 (d, J = 7.2 Hz, 2H), 7.62 (m, 1H), 7.50 (t, J = 7.2 Hz,
4H), 7.35 (m, 4H), 6.03 (t, J = 9.6 Hz, 1H), 5.29 (d, J = 3.3
Hz, 1H), 5.09 (m, 2H), 5.06 (t, 1H, J= 9.3 Hz, 1H), 4.99 (dd,
1H, J=7.8 Hz, J=10.5 Hz, 1H), 4.89-4.77 (m, 2H), 4.75 (d,
1H, J= 12.0 Hz), 4.68 (d, 1H, J= 7.8 Hz), 4.44 (dd, 1H, J=
12.0 Hz, J = 5.1 Hz, 1H), 4.27 (d, 1H, J = 7.8 Hz, 1H),
4.23-4.19 (m, 1H), 4.84 (dd, J = 10.2 Hz, J = 3.6 Hz, 1H),
4.50-4.46 (m, 2H), 4.11-3.97 (m, 4H), 3.79 (t, J = 6.9 Hz,
1H), 3.67-3.59 (m, 2H), 3.28 (m, 1H), 3.42 (s, 3H), 2.11, 2.04,
2.02, 1.92 (each s, each CH3);
13C NMR (75 MHz, CDCl3) δ
(ppm): 170.4, 170.2, 170.1 (2s), 169.8, 169.7, 169.0, 166.1,
166.0, 165.0, 133.4 (each C), 130-128.4 (15  CH), 101.1,
100.1, 96.9, 75.6, 73.0, 72.7, 72.4, 72.2, 71.1, 70.7, 70.4, 69.0
(each CH), 62.8, 61.8, 60.9 (each CH2), 55.6 (CH), 20.9, 20.8,
20.7, 20.6 (each CH3); HRMS (ESI) found 1147.3267 [M þ
Naþ], C54H60NaO26 requires 1147.3271.
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-(1f4)-2,3,6-tri-
O-acetyl-β-D-glucopyranosyl-(1f4)-2,3,6-tri-O-benzoyl-β-D-glu-
copyranosyl Azide 18. Trisaccharide 17 (1.17 g, 1.00 mmol) was
dissolved in acetic anhydride (10 mL) and an acetic anhydri-
de-sulfuric acid mixture (1:50, 20 mL) was added and the
mixture was stirred for 2 h at rt. Dichloromethane was then
added (100 mL) and the organic layer washed with water (100
mL), satd NaHCO3 (100 mL), and water (100 mL), dried
(MgSO4), and filtered. The solvent was removed under dimin-
ished pressure. Chromatography of the residue (cyclo-
hexane-EtOAc, 7:3) gave the glycosyl acetate intermediate as
a white solid (0.81 g, 70%). Reaction of this glycosyl acetate (0.8
g, 0.69 mmol) with azidotrimethylsilane (0.4 g, 3.45 mmol) and
SnCl4 as described for the preparation of 15 gave the title
compound (0.6 g, 77%); mp 102 C; [R]20D þ7 (c 0.3, CH2Cl2);
1H NMR (300 MHz, CDCl3) δ (ppm) 8.09 (d, J= 7.2 Hz, 2H),
8.00 (d, d, J= 7.2 Hz, 2H), 7.91 (d, J= 7.2 Hz, 2H), 7.63 (m,
1H), 7.53-7.48 (m, 4H), 7.37-7.27 (m, 4H), 5.75 (t, J=9.3 Hz,
1H), 5.33 (t, J= 9.0 Hz, 1H), 5.29 (s, 1H), 5.05 (t, 1H, J= 9.0
Hz, 1H), 4.98 (dd, J= 9.0 Hz, J= 7.5 Hz, 1H), 4.90-4.80 (m,
4H), 4.65 (d, J=7.8Hz, 1H), 4.44 (dd, J=12.0Hz, J=4.8Hz,
1H), 4.26 (d, J=7.8Hz, 1H), 4.15 (dd, J=9.0Hz, 1H), 4.04 (m,
4H), 3.95 (d, J=10.5 Hz, 1H), 3.77 (t, J=6.9 Hz, 1H), 3.59 (t,
J=6.9Hz, 1H), 3.50 (dd, 1H, J=10.5Hz, J=5.1Hz), 3.28 (m,
1H), 2.11, 2.00, 1.97, 1.93 (each s, 7CH3); 13CNMR(75MHz,
CDCl3) δ (ppm) 170.4, 170.2, 170.1, 170.0, 169.8, 169.6, 169.0,
166.0, 165.2, 165.0, 133.6 (each C), 130-128.5 (15CH), 101.0,
100.3, 88.0, 76.1, 75.6, 75.3, 72.9 (2s), 72.8, 72.0, 71.5, 71.0, 70.7,
69.0, 66.6 (each CH), 62.4, 61.8, 60.8 (each CH2), 20.9, 20.8,
20.7, 20.6 (each CH3); HRMS (ESI) found 1158.3213 [M þ
Naþ], C53H57N3NaO25 requires 1158.3179.
N,N0-Di(β-D-galactopyranosyl-(1f4)-β-D-glucopyranosyl-
(1f4)-β-D-glucopyranosyl)terephtalamide 4. Catalytic hydroge-
nation of azide 18 (0.21 g, 0.176 mmol) as described for 15
gave an amine intermediate. Reaction of the amine (0.25 g,
0.22 mmol) with terephthaloyl chloride (44 mg, 0.22 mmol) as
described for the preparation of 15 and following chromatog-
raphy (EtOAc-cyclohexane, 60:40 to 55:45) yielded the pro-
tected divalent compound as a white powder (63 mg, 25%).
This intermediate (23.5 mg, 10 μmol) was dissolved in dry
MeOH (1 mL). Potassium carbonate was then added (15 mg),
and the resulting solution was stirred for 20 h at rt. The solvent
was removedunder reducedpressure andwaterwas added (2mL).
Amberlite IR-120(plus) was added, until the pH reached 6.
Water was then removed by lyophilization to obtain 4 (white
powder) in quantitative yield; mp 187 C; [R]20D -4 (c 0.1,
CH2Cl2);
1H NMR (300 MHz, D2O) δ (ppm) 7.94 (s, 4H), 5.27
(d, J=9.0Hz, 2H), 4.54 (d, J=8.1Hz, 2H), 4.48 (d, J=7.8Hz,
2H), 4.00-3.54 (m, 36H), 3.41 (t, J=8.7Hz, 2H); 13CNMR (75
MHz, CDCl3) δ (ppm) 173.8, 139.4 (eachC), 130.8, 105.8, 105.2,
82.0, 81.0, 80.8, 79.4, 78.2, 77.9, 77.7, 77.0, 75.7, 75.4, 74.4, 73.8,
71.4 (each CH), 63.9, 62.8, 62.7 (each CH2); HRMS (ESI) found
1159.3639 [M þ Naþ], C44H68N2NaO32 requires 1159.3653.
2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl-(1f4)-2,3,6-
tri-O-benzoyl-β-D-glucopyranosyl-(1f3)-1,2:5,6-di-O-isopropy-
lidene-β-D-glucofuranoside 21. Glycosidation coupling of tri-
chloroacetimidate 19 (1.08 g, 0.89 mmol) with 1,2:5,6-di-O-
isopropylidene-R-D-glucofuranose 20 (0.193 g, 0.742 mmol)
as described for 13 gave, after chromatography (cyclo-
hexane-EtOAc, gradient elution, 4:1 to 3:1), 21 as a white foam
(0.69 g, 71%); Rf 0.36 (cyclohexane-EtOAc, 2:1); [R]20D þ33.2
(c 2.5, CHCl3);
1HNMR (500MHz, CDCl3) δ 8.02-7.94 (m, 10
H), 7.90 (d, J=7.3Hz, 2H), 7.72 (dd, J=8.4, J=1.1Hz, 2H),
7.65-7.45 (m, 8H), 7.44-7.28 (m, 9H), 7.23-7.14 (m, 4H), 5.79
(t, J=9.4Hz, 1H), 5.75-5.70 (m, 2H), 5.46 (d, J=3.7Hz, 1H),
5.41 (dd, J = 6.7, 3.0 Hz, 1H), 5.40 (dd, J = 6.4, 2.9 Hz, 1H),
4.89 (d, J=7.9 Hz, 1H), 4.82 (d, J=7.9 Hz, 1H), 4.59 (dd, J=
12.1 Hz, J= 1.5 Hz, 1H), 4.49 (dd, J=-12.2 Hz, J= 4.2 Hz,
1H), 4.32-4.17 (m, 5H), 3.97 (dd, J=8.6 Hz, J=6.5 Hz, 1H),
3.92 (dd, J=8.5Hz, J=6.0Hz, 1H), 3.91 (t, J=6.4, 1H), 3.82
(ddd, J=9.9 Hz, J=3.9 Hz, J=1.8 Hz, 1H), 3.75 (d, J=6.7
Hz, 2H), 1.39, 1.32, 1.13, 1.09 (each s, each 3H); 13C NMR (125
MHz, CDCl3) δ 165.8, 165.5, 165.4, 165.3, 165.2, 164.8 (2s)
(each C), 133.5, 133.4 (2s), 133.3, 133.2, 129.7 (4s), 129.6 (2s),
129.5, 129.4 (2s), 129.1, 128.9, 128.7, 128.6 (3s), 128.5, 128.3,
128.2 (each CH), 111.9, 108.5 (each C), 104.9, 101.1, 99.8, 82.7,
81.4, 80.4, 75.9, 73.4, 73.0, 72.7, 71.7 (2s), 71.4, 69.9, 67.5 (each
CH), 67.0, 66.1, 62.0 (each CH2), 26.6, 26.5, 25.9, 25.0 (each
CH3); IR (KBr) 3064, 2985, 1730, 1603, 1453, 1269, 1093, 1070
cm-1; HRMS (ESI) found 1335.3987 [MþNa]þ, C73H68NaO23
requires 1335.4049.
2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl-(1f4)-2,3,6-
tri-O-benzoyl-β-D-glucopyranosyl-(1f3)-2,4,6-tri-O-acetyl-β-D-
glucopyranosyl Amine 22.A solution of 21 (0.59 g, 0.45mmol) in
80% acetic acid (100 mL) was heated at 100 C for 16 h. The
solvents were then removed under diminished pressure. Metha-
nol (2 10 mL) and CH2Cl2 (2 10 mL) were evaporated from
the residue to give the desired trisaccharide intermediate as a
white foam (quantitative yield, HRMS (ESI): 1255.3361 [M þ
Na]þ). This intermediate was dissolved in pyridine (5 mL) and
acetic anhydride (5mL) and themixturewas stirred for 15 h. The
volatile reagents were removed and toluene (2  10 mL) and
CH2Cl2 (2  10 mL) were evaporated from the residue. Chro-
matography (cyclohexane-EtOAc, gradient elution, 3.5:1 to
1:1) gave the protected glycosyl acetate intermediate as a white
amorphous solid (0.51 g, 81% over two steps, mixture of
anomers, R:β= 3:2). Reaction of this glycosyl acetate (0.492 g,
0.351 mmol) with azidotrimethylsilane (0.155 mL, 0.878 mmol)
as described for preparation of 15 gave, after chromatography
(cycohexane-EtOAc, gradient elution, 3:1 to 1:1), the glycosyl
azide precursor to 22 as a white foam (0.294 g, 61%). Catalytic
hydrogenation of this glycosyl azide (0.252 g, 0.182 mmol) as
described for 15 gave, after chromatography (cyclohexane-
EtOAc, 1:1 to EtOAc-CH2Cl2, 9:1), 22 as a white foam
(0.179 g, 72%); Rf 0.44 (EtOAc-CH2Cl2, 9:1); [R]20D þ12.6 (c
1.04, CHCl3);
1H NMR (500 MHz, CDCl3) δ 8.04-7.95 (m,
8H), 7.90-7.82 (m, 4H), 7.71 (dd, J=8.2 Hz, J=1.0 Hz, 2H),
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7.64-7.56 (m, 3H), 7.55-7.28 (m, 14H), 7.20 (t, J = 7.9 Hz,
2H), 7.13 (t, J=7.8Hz, 2H), 5.79 (t, J=9.5Hz, 1H), 5.71-5.67
(m, 2H), 5.37 (dd, J= 9.8 Hz, J= 8.0 Hz, 1H), 5.32 (dd, J=
10.3 Hz, J=3.4 Hz, 1H), 4.93 (t, J=9.6 Hz, 1H), 4.85 (d, J=
7.9 Hz, 1H), 4.80 (d, J= 7.9 Hz, 1H), 4.68 (t, J= 9.4 Hz, 1H),
4.58 (dd, J= 12.2 Hz, J= 1.4 Hz, 1H), 4.47 (dd, J= 12.3 Hz,
J = 4.1 Hz, 1H), 4.29 (t, J= 9.5 Hz, 1H), 4.07-4.04 (m, 2H),
3.95 (d, J= 9.0 Hz, 1H), 3.87-3.76 (m, 4H), 3.66 (tt, J= 10.1
Hz, J = 5.2 Hz, 1H), 3.47 (td, J = 10.1 Hz, J = 3.6 Hz, 1H),
2.05, 1.92, 1.72 (each s, eachCH3);
13CNMR(125MHz,CDCl3)
δ 171.0, 169.7, 168.4, 165.9, 165.8, 165.7, 165.6, 165.5, 165.4,
165.0 (each C), 133.9, 133.8 (2s), 133.7, 133.5 (2s), 13.4, 130.2,
130.1, 130.0, 129.9 (3s) (each CH), 129.7 (CH), 129.7 (2s), 129.5,
129.1 (each C), 128.9 (each CH), 128.9 (C), 128.8 (CH), 128.8
(C), 128.5 (2s), 128.4 (each CH), 101.4, 101.2, 85.4, 79.5, 75.9,
73.9, 73.3, 73.1, 73.0, 72.2, 72.0, 71.7, 70.2, 68.7, 67.8 (each CH),
62.8, 61.3 (each CH2), 21.2, 21.0, 20.6 (each CH3); IR (film on
NaCl) 2958, 1730, 1375, 1267, 1092, 1068, 1028 cm-1; HRMS
(ESI) found 1358.4141 [M þ H]þ, C73H68NO25 requires
1358.4080.
N,N0-Di(β-D-galactopyranosyl-(1f4)-β-D-glucopyranosyl-
(1f3)-β-D-glucopyranosyl)terephthalamide 5. Reaction of the
amine 22 (48.5 mg, 0.036 mmol) with terephthaloyl chloride as
described for 10 gave, after chromatography (EtOAc-cyclo-
hexane, gradient elution, 1:1 to 3:2), the protected diamide as a
white amorphous solid (28.6 mg, 56%). Deprotection of the
diamide (27 mg, 0.01 mmol) with the Zemplen procedure gave 5
(5.6 mg, 52%) as a white solid after semipreparative HPLC;
[R]20D þ512 (c 0.16); 1H NMR (500 MHz, D2O, 30 C) δ 7.93
(s, 4H), 5.24 (d, J= 9.3 Hz, 2H), 4.83 (d, J= 8.0 Hz, 2H), 4.45
(d, J=7.8Hz, 2H), 3.99 (dd, J=12.2Hz, J=1.8Hz, 2H), 3.92
(d, J = 2.9 Hz, 2H), 3.91-3.86 (m, 2H), 3.84-3.74 (m, 10H),
3.74-3.61 (m, 14H), 3.61-3.57 (m, 2H), 3.54 (dd, J = 9.9 Hz,
J = 7.8 Hz, 2H), 3.42 (dd, J = 9.3 Hz, J = 8.0 Hz, 2H); 13C
NMR (125 MHz, D2O) δ 171.2, 136.7 (each C), 128.1, 103.2,
102.8, 80.0, 85.2, 78.6, 77.7, 75.6, 75.1, 74.5, 73.4, 72.8, 71.7,
71.2, 68.8, 68.0 (each CH), 61.3, 60.8, 60.3 (each CH2); IR (KBr)
3473-3313 (br s), 1657, 1552, 1385, 1071, 1043 cm-1; HRMS
(ESI) found 1135.3638 [M - H]-, C44H67N2O32 requires
1135.367.
2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl-(1f4)-2,3,6-
tri-O-benzoyl-β-D-glucopyranosyl)-(1f3)-2,4-di-O-acetyl-1-azi-
do-1-deoxy-β-D-glucopyranuronic Acid 25. Reaction of the tri-
chloroacetimidate 19 (1.64 g, 1.35 mmol) with acceptor 235,19c
(0.745 g, 2.18 mmol) as described for 13 gave, after chromatog-
raphy (cyclohexane-toluene-EtOAc, 3:2:1), the glycosidic
product as a white foam (0.62 g, 33%). To this intermediate
(0.264 g, 0.189 mmol) in dry CH3CN (2 mL) at 0 C were added
Pd(Ph3)4 (0.022 g, 0.019mmol) and pyrrolidine (0.016mL, 0.189
mmol), respectively, with stirring for 1 h. The mixture was then
filtered throughCelite and the solvent was removed. The residue
was dissolved in EtOAc and the organic layer was washed with
H2O (2 15 mL). The water layer was then washed with EtOAc
(3  15 mL) and the organic layers combined, dried (MgSO4),
and filtered, then solvent was removed under diminished pres-
sure to give 25 (0.238 g, 92%); [R]20D þ6.6 (c 2.55, CHCl3); 1H
NMR (600 MHz, CDCl3) δ 8.02-7.92 (m, 7H), 7.86 (dd, J =
13.4Hz, J=7.6Hz, 4H), 7.71 (d, J=7.4Hz, 2H), 7.67 (dd, J=
12.0 Hz, J= 7.2 Hz, 2H), 7.64-7.28 (m, 16H), 7.20 (t, J= 7.8
Hz, 2H), 7.12 (t, J = 7.8 Hz, 2H), 5.76 (t, J = 9.4 Hz, 1H),
5.70-5.66 (m, 2H), 5.37 (d, J= 8.1 Hz, 1H), 5.31 (dd, J= 10.3
Hz, J= 3.4 Hz, 1H), 5.14-5.02 (br s, 1H), 4.84-4.81 (m, 1H),
4.79 (overlapping d, J=7.9Hz, 2H), 4.54 (d, J=11.0 Hz, 1H),
4.46 (dd, J= 12.2 Hz, J= 3.9 Hz, 1H), 4.31 (broad d, J= 8.1
Hz, 1H), 4.27 (t, J= 9.4 Hz, 1H), 3.94-3.71 (m, 5H), 3.66 (dd,
J=11.1 Hz, J=6.5 Hz, 1H), 1.85, 1.70 (each s, each CH3);
13C
NMR (150 MHz, CDCl3) δ 170.4, 169.2, 168.4, 165.7, 165.5,
165.4 (2s), 165.2 (2s), 164.8, 133.6 (each C), 133.5 (CH), 133.2
(C), 132.1 (2s), 131.9 (2s), 129.9, 129.8, 129.7 (2s), 129.6 (2s),
129.5 (eachCH), 129.5, 129.4, 129.3, 128.9 (eachC), 128.7 (CH),
128.7 (C), 128.6, 128.5 (2s), 128.4, 128.2, 79.0, 76.0, 75.5, 73.0,
72.8, 72.0, 71.9, 71.7, 71.4, 69.9, 69.5, 67.5 (each CH), 62.5, 61.0
(CH2), 20.6, 20.5 (each CH3); IR (film on NaCl) 3483-3305
(br s), 2121, 1746, 1619, 1429, 1376, 1232, 1046, 901 cm-1;
LRMS (ES) 1355.2 [M - H]-; HRMS (ESI) found 1378.3523
[M þ Na]þ, C71H61NaN3O25 requires 1378.3492.
1,4-Di[(β-D-galactopyranosyl-(1f4)-β-D-glucopyranosyl)-(1f3)-
1-azido-1-deoxy-β-D-glucopyranuronamidomethyl]benzene 6.
Acid 25 (117 mg, 0.88 mmol), HOBt (27 mg, 0.201 mmol),
p-xylylenediamine (5 mg, 0.04 mmol), and DIPEA (0.018 mL,
0.1mmol)were dissolved in dryDMF (0.8mL) at 0 CunderN2.
HATU (43 mg, 0.11 mmol) was added and the reaction was
stirred for 1 h at 0 C and then overnight at rt. Ethyl acetate was
added and the mixture was washed with H2O (2  10 mL), the
organic layer was separated, dried (MgSO4), and filtered, and
the solvent was removed. Chromatography of the residue
(toluene-EtOAc, 2:1) gave the intermediate protected diamide
as a pale yellow solid (72 mg, 65%). To this protected diamide
(33 mg, 0.012 mmol) in MeOH-CH2Cl2 (2.5 mL, 4:1) was
slowly added a solution of NaOMe (0.1 mL, 25 M in MeOH)
and the resulting mixture was stirred for 3 h at 0 C. Solid CO2
was added, the mixture was stirred for 20 min, and the solvent
was then removed under diminished pressure. The residue was
dissolved in water and then lyophilized to give 6 as a white
powder. 1H NMR (600 MHz, D2O) δ 7.32 (s, 4H), 4.85 (d,
J = 8.9 Hz, 2H), 4.80 (d, J= 8.0 Hz, 2H), 4.46 (s, 4H), 4.44 (d,
J=7.9Hz, 2H), 4.05 (d, J=9.9Hz, 2H), 3.99 (dd, J=12.2Hz,
J= 1.7 Hz, 2H), 3.93 (d, J= 3.2 Hz, 2H), 3.85 (t, J= 9.1 Hz,
2H), 3.83-3.70 (m, 10H), 3.69-3.64 (m, 6H), 3.63-3.59 (m,
2H), 3.55 (dd, J=9.0Hz, J=8.9Hz, 4H), 3.40 (dd, J =8.3Hz,
J=8.8Hz, 2H); 13CNMR(150MHz,D2O)δ 169.9, 136.9 (each
C), 127.7, 103.2, 102.7, 90.2, 83.4, 78.7, 76.9, 75.6, 75.1, 74.4,
73.4, 72.8, 72.5, 71.2, 69.8, 68.8 (each CH), 61.3, 60.4, 42.8 (each
CH2); IR (KBr) 3483-3305 (br s), 2121, 1660, 1385, 1277, 1070
cm-1; LRMS (ES) 1185.4 [M - H]-; HRMS (ESI) found
1209.3837 [M þ Na]þ, C44H66N8NaO30 requires 1209.3783,
and found 1185.3833 [M - H]-, C44H65N8O30 requires
1185.3807.
Allyl 2,3,4,6-Tetra-O-acetyl-r-D-mannopyranosyl-(1f3)-2,4-
di-O-acetyl-1-O-allyl-r-D-glucopyranuronate 28. Deacetylation
of 2719b (940 mg, 2.61 mmol) gave allyl R-D-glucopyranosiduro-
nic acid as a yellow foam (589mg, 96%). This intermediate (1.56
g, 6.30 mmol) was suspended in acetic anhydride (23 mL) in the
presence ofmolecular sieves and stirred in a preheated bath at 85
C for 2 h. The solvent was coevaporated with toluene to give a
brown oil that was dried under high vacuum. The oil was
dissolved in cyclohexane-EtOAc (1:1) then filtered, and the
filtrate was passed through a short column of silica gel eluting
with cyclohexane-EtOAc (1:1). This gave a 6,3-lactone inter-
mediate as a yellow oil (1.63 g, 86%), which was used in the next
reaction without further purification. Allyl alcohol (2.5 mL,
36.7 mmol) was added to a solution of the 6,3 lactone inter-
mediate (1.63 g, 5.33mmol) in dryTHF (8mL) in the presence of
NaOAc (217 mg, 2.65 mmol) and molecular sieves at rt and
underN2. Themixture was stirred at rt for 24 h then filtered, and
the filtrate was evaporated under reduced pressure to give a
brown oil. This oil was dissolved in dichloromethane (30 mL)
and washed with brine. The aq phase was further extracted with
dichloromethane (2  15 mL) and the combined organic
extracts were dried (MgSO4) and filtered, then the solvent was
removed under reduced pressure. Chromatography of the re-
sidue (cyclohexane-EtOAc, 2:1) gave 28 as a white solid (1.03 g,
75%); Rf 0.45 (cyclohexane-EtOAc, 1:1); [R]D þ20.8 (c 0.18,
CHCl3);
1H NMR (CDCl3, 300 MHz) δ 5.98-5.78 (m, 2H),
5.39-5.20 (m, 4H), 5.17-5.15 (d, J=3.6Hz, 1H), 5.11-5.04 (t,
J= 9.6 Hz, 1H), 4.83-4.79 (dd, J= 3.9 Hz, J= 10.2 Hz, 1H),
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4.69-4.55 (m, 2H), 4.31-4.28 (d, J= 10.2, 1H), 4.25-4.09 (m
and overlapping t, J=9.6Hz, 2H), 4.06-3.99 (m, 1H,), 2.45 (d,
J = 5.4 Hz, 1H), 2.13, 2.08 (each s, 3H, each CH3);
13C NMR
(CDCl3, 75 MHz) δ 170.7, 170.4, 167.8 (each C), 133.0, 131.2
(each CH), 118.5, 118.2 (each CH2), 95.4, 72.9, 72.0, 69.4 (each
CH), 69.1 (CH2), 68.7 (CH), 66.6 (CH2), 20.9, 20.8 (each CH3);
IR (film from dichloromethane) 3480, 2996, 1748, 1374, 1230,
1050 cm-1; HRMS (ESI) found 359.1349 [M þ H]þ, C16H23O9
requires 359.1342.
2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl-(1f4)-2,3,6-
tri-O-benzoyl-β-D-glucopyranosyl-(1f3)-2,4-di-O-acetyl-1-O-
allyl-r-D-glucopyranuronic Acid 29. Glycoside coupling reac-
tion of acceptor 28 (1.31 g, 3.65 mmol) and trichloroacetimi-
date 19 (3.22 g, 2.65 mmol) as described for 13 gave, after
chromatography (eluant cyclohexane-toluene-EtOAc 3:2:1
to 5:4:2), the protected trisaccharide intermediate as a white
solid (3.11 g, 83%). To this protected trisaccharide (1.45 g,
1.027 mmol) in dry acetonitrile (8 mL), cooled on an ice bath
and under N2, tetrakis(triphenylphosphine)palladium (117
mg, 0.10 mmol) was added followed by pyrrolidine (85 μL,
1.032 mmol). The reaction mixture was stirred on an ice bath
for 1 h and then the solvent was removed under diminished
pressure. The residue was dissolved in dichloromethane and
washed with 0.1MHCl and brine and then dried (MgSO4) and
filtered, then the solvent was removed under diminished
pressure. The residue was filtered through a short column of
silica gel (eluant: dichloromethane thenMeOH) to give 29 as a
pale yellow solid (980 mg, 70%); Rf 0.15 (dichloromethane-
MeOH, 95:5); [R]20Dþ4.26 (c 0.26, CHCl3); 1HNMR (CDCl3,
600 MHz) δ (ppm) 8.00-7.96 (m, 8H), 7.88 (d, J = 7.2 Hz,
2H), 7.79 (d, J = 6 Hz, 2H), 7.72 (d, J = 7.2 Hz, 2H),
7.62-7.56 (m, 2H), 7.50-7.31 (m, 15H), 7.21-7.19 (t, J =
7.8Hz, 2H), 7.14-7.12 (m, 2H), 5.77-5.67 (m, 4H), 5.36-5.32
(m, 2H), 5.18-5.15 (d, J = 17 Hz, 1H), 5.11-4.94 (m, 3H),
4.86 (d, J= 6.6 Hz, 1H), 4.81 (d, J= 7.8 Hz, 1H), 4.60-4.53
(m, 2H), 4.47-4.45 (m, 1H), 4.27-4.24 (t, J = 8.4 Hz, 1H),
4.11-4.01 (m, 3H), 3.90-3.69 (m, 5H), 1.76, 1.67 (each s, 3H);
13C NMR (CDCl3, 100 MHz) δ 169.4, 165.7, 165.6, 165.5,
165.4, 165.2, 164.8 (each C), 133.5, 133.2, 129.9, 129.8, 129.7,
129.6 (2s) (each CH), 129.6 (C), 129.5, 129.4, 129.2, 128.9,
128.7, 128.6, 128.5, 128.2 (each CH), 118.0 (CH2), 101.1,
100.9, 95.0, 75.6, 73.1, 72.7, 72.1, 71.7, 71.4, 69.8 (each CH),
68.9 (CH2), 67.5 (CH), 62.4, 61.0 (each CH2), 20.5, 20.4 (each
CH3); IR (film from dichloromethane) 3598, 3374, 1729, 1602,
1423, 1371, 1267, 1103, 1050 cm-1; HRMS (ESI) found
1393.3729 [M þ Na]þ, C74H66O26 requires 1393.3740.
1,4-Di[2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl-(1f4)-
2,3,6-tri-O-benzoyl-β-D-glucopyranosyl-(1f3)-2,4-di-O-acetyl-
1-O-allyl-r-D-glucopyranuronamidomethyl]benzene 30. To acid
29 (980mg, 0.71mmol) in dryDMF (7.5mL) and underN2were
added HOBt monohydrate (134 mg, 0.98 mmol) followed by p-
xylylenediamine (41 mg, 0.3 mmol). Diisopropylethylamine
(180 μL, 1.07 mmol) was added and the mixture became cloudy,
then it was cooled on an ice bath and HATU (350 mg, 0.92
mmol) was added. The reactionmixture was allowed to attain rt
and was then stirred for 15 h. Dichloromethane was added and
the mixture was washed with water. The aq phase was extracted
with dichloromethane and the combined organic extracts were
dried (MgSO4) and filtered and the solvent was removed under
diminished pressure. Chromatography (toluene-EtOAc, 2.5:1
and EtOAc) gave 30 as a white solid (629 mg, 74%); Rf 0.55
(toluene-EtOAc, 1:1); [R]20D þ2.41 (c 0.25, CHCl3); 1H NMR
(CDCl3, 600MHz) δ (ppm) 8.02-7.97 (m, 14H), 7.87 (d, J=7.2
Hz, 4H), 7.81 (d, J = 7.2 Hz, 4H), 7.71 (d, J = 7.2 Hz, 4H),
7.62-7.59 (m, 4H), 7.57-7.55 (m, 2H), 7.51-7.30 (m, 24H),
7.26-7.23 (t, J=6Hz, 4H), 7.20 (s, 4H) overlapping 7.20-7.11
(m, 10H), 6.52-6.50 (t, J=6Hz, 2H), 5.80-5.77 (t, J=9.6Hz,
2H), 5.77-5.68 (m, 6H), 5.36-5.34 (dd, J=8.4Hz, J=9.3Hz,
2H), 5.34-5.32 (dd, J = 10.2 Hz, J = 3.0 Hz, 2H), 5.21-5.14
(m, 4H), 5.03-5.00 (t, J = 9.6, 2H), 5.00 (d, J = 3.6 Hz, 2H),
4.87 (d, J=7.8Hz, 2H), 4.81 (d, J=8.4Hz, 2H), 4.58-4.54 (m,
4H), 4.48-4.46 (dd, J = 4.5 Hz, J = 13.2 Hz, 2H), 4.38-4.30
(m, 4H), 4.30-4.27 (t, J=9.6Hz, 2H), 4.18-4.15 (t, J=9.6Hz,
2H), 4.13 (d, J=10 Hz, 2H), 4.09-4.05 (m, 2H), 3.89-386 (m,
2H), 3.82-3.77 (m, 6H), 3.68-3.66 (m, 2H), 1.82, 1.78 (each s,
3H); 13C NMR (CDCl3, 150 MHz) δ (ppm) 169.5, 169.4, 167.3,
165.7, 165.6, 165.5, 165.4, 165.2, 165.1, 164.8, 137.0 (each C),
133.6, 133.5 (2s), 133.4, 133.2 (eachCH), 133.2 (C), 133.1, 132.7,
129.9, 129.8, 129.7 (2s) (each CH), 129.6 (2s) (C), 129.6, 129.5
(2s) (each CH), 129.4, 129.3, 128.9 (each C), 128.7 (2s) (each
CH), 128.6 (C), 128.5, 128.3 (2s), 128.2 (each CH), 118.5 (CH2),
101.2, 100.9, 94.5, 75.7, 75.6, 73.0, 72.9, 72.8, 72.1, 71.7, 71.5,
69.9, 69.5 (each CH), 69.2 (CH2), 68.7, 67.6 (each CH),
62.4, 61.1, 43.7 (each CH2), 20.5, 20.4 (each CH3); IR (film
from dichloromethane) 3432, 3343, 3064, 2944, 1729, 1687,
1585, 1527, 1452, 1371, 1263, 1099, 1051 cm-1; HRMS (ESI)
found 1421.4327 [M þ 2H]2þ, C156H140N2O50 requires m/2z
1421.4315.
Macrocyclic Compound 31 and Acyclic Compound 32. A
degassed solution of the diamide 30 (629 mg, 0.22 mmol) in
dry dichloromethane (190 mL, 1.15 mM) and under N2 was
treated with Grubbs-I catalyst (53 mg, ∼9%) for 60 h. The
solvent was evaporated, then the resulting black solid was
dissolved and subjected to fractionation through a short column
of silica gel (toluene-EtOAc, 2:1) yielding amixture of products
that was used in the next reaction without further purification.
Three cycles of catalytic hydrogenation of the mixture (530 mg)
using the H-Cube (70 C) hydrogenation apparatus with Pd as
catalyst and EtOAc as solvent and subsequent chromatography
(toluene-cyclohexane-EtOAc, 3:1:1 to 1:1:1) gave both 31 (265
mg, 43%) and 32 (233 mg, 44%). Analytical data for 32:Rf 0.75
(toluene-EtOAc 1:1); [R]D þ2.86 (c 0.24, CHCl3); 1H NMR
(CDCl3, 600 MHz) δ 8.02-7.96 (m, 14H), 7.86 (d, J= 7.2 Hz,
4H), 7.82 (d, J = 7.2 Hz, 4H), 7.71 (d, J = 7.2 Hz, 4H),
7.63-7.60 (t, J = 7.2 Hz, 4H), 7.57-7.55 (t, J = 7.8 Hz, 2H),
7.52-7.30 (m, 28H), 7.21-7.19 (t, J=7.8 Hz, 4H) overlapping
with 7.20 (s, 4H), 7.16-7.12 (m, 6H), 6.52-6.49 (t, J= 5.4 Hz,
2H, NH), 5.80-5.77 (t, J = 9.6 Hz, 2H), 5.72-5.68 (m, 4H),
5.37-5.34 (dd, J = 8.4 Hz, J = 10.2 Hz, 2H), 5.34-5.31 (dd,
J=5.4Hz, J=10.2 Hz, 2H), 5.01-4.98 (t, J=9Hz, 2H), 4.96
(d, J=3.0Hz, 2H), 4.88 (d, J=7.8Hz, 2H), 4.81 (d, J=7.8Hz,
2H), 4.59-4.57 (m, 2H), 4.52-4.50 (dd, J=3.6Hz, J=9.8Hz),
4.49-4.46 (dd, J=3.6 Hz, J=12Hz, 2H), 4.37-4.27 (m, 6H),
4.14-4.09 (m, 4H), 3.82-376 (m, 6H), 3.68-3.65 (m, 2H),
3.54-3.50 (m, 2H), 3.26-3.22 (m, 2H), 1.82, 1.78 (each s, 3H),
1.53-1.47 (m, 4H), 0.85-0.83 (t, J = 6.0 Hz, 6H); 13C NMR
(CDCl3, 150 MHz) δ 169.5 (2 s), 167.4, 165.7, 165.6, 165.5,
165.4, 165.2, 165.1, 164.8, 137.0, 133.6 (eachC), 133.5 (2s), 133.2
(each CH), 133.2, 133.1 (each C), 129.9, 129.8, 129.7 (3s), 129.5
(CH), 129.4, 129.3, 128.9 (C), 128.7(2s), 128.6, 128.3 (3s) (each
CH), 101.2, 100.9, 95.2, 75.8, 75.6, 73.2, 73.0, 72.8, 72.1, 71.8,
71.5 (each CH), 70.5 (CH2), 69.9, 69.6, 68.5, 67.6 (each CH),
62.5, 61.1, 42.7, 22.4 (each CH2), 20.5, 20.4, 10.4 (each CH3); IR
(film fromdichloromethane) 3394, 3264, 2967, 2856, 1731, 1681,
1585, 1521, 1452, 1369, 1265, 1176, 1085, 1070, 1025 cm-1;
HRMS (ESI) found 1423.4458 [M þ 2H]2þ, C156H144N2O50
requires 1423.4472. Anal. Calcd for C156H144N2O50: C 65.82, H
5.10, N 0.98. Found: C 65.51,H 5.26,N 0.83. Analytical data for
31: Rf= 0.7 (toluene-EtOAc 1:1); [R]D þ0.61 (c 0.18, CHCl3);
1HNMR (CDCl3, 600MHz) δ 8.02-7.96 (m, 14H), 7.87 (d, J=
7.2 Hz, 4H), 7.83 (d, J= 7.2 Hz, 4H), 7.71 (d, J= 7.2 Hz, 4H),
7.62-7.60 (t, J = 6.6 Hz, 4H), 7.58-7.54 (m, 2H), 7.52-7.31
(m, 28H), 7.27-7.24 (t, J=7.8Hz, 4H), 7.26 (s, 4H), 7.21-7.11
(m, 6H), 6.74-6.72 (dd, J=3.6Hz, J=9.6Hz, 2H), 5.79-5.76
(t, J= 9.0 Hz, 2H), 5.69-5.65 (m, 4H), 5.38-5.36 (dd, J= 7.9
Hz, J= 10.0 Hz, 2H), 5.35-5.32 (dd, J= 3.3 Hz, J= 8.6 Hz,
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2H), 4.99-4.96 (m, 4H), 4.86 (d, J=7.7Hz, 2H), 4.85-4.77 (m,
4H), 4.55-4.51 (m, 4H), 4.49-4.45 (m, 2H), 4.30-4.27 (t, J=
9.6Hz, 2H), 4.09-4.06 (t, J=9.0Hz, 2H), 3.95 (d, J=10.8Hz,
2H), 3.82-374 (m, 8H), 3.69-3.65 (m, 2H), 3.27-3.23 (m, 2H),
3.19-3.14 (m, 2H), 1.85, 1.76 (each s, each 3H), 1.48-1.42 (m,
2H), 1.31-1.22 (m, 2H); 13C NMR (CDCl3, 150 MHz) δ 169.5
(2s, 167.3, 166.0, 165.7, 165.6, 165.3, 165.2, 165.0, 164.8 (each
CO), 138.2, 133.6 (C), 133.5 (2s, CH), 133.4 (C), 133.3 (CH),
133.2, (C), 129.9, 129.8, 129.7 (2s), 129.6 (2s), 129.5 (2s), 129.4
(each CH), 129.2 (C), 128.9, 128.7, 128.6 (3s), 128.3 (2s), 128.2
(each CH), 127.9 (C), 127.8 (CH), 127.8, 127.7 (each C), 101.0,
100.9, 96.1, 75.8, 75.5, 73.0, 72.9, 72.8, 72.1, 71.7, 71.5, 69.9
(each CH), 69.4 (CH2), 69.3, 67.9, 67.6 (each CH), 62.4, 61.1,
42.2, 25.56 (each CH2), 20.4, 20.3 (each CH3); IR (film from
dichloromethane) 3598, 3374, 1729, 1602, 1423, 1371, 1267,
1103, 1050, 3405, 3315, 3062, 2980, 2921, 2856, 1731, 1683,
1600, 1523, 1452, 1399, 1315, 1263, 1067, 1027 cm-1; HRMS
(ESI) found m/2z 1408.4218 [M þ 2H]2þ, C154H138N2O50
requires 1408.4237.
1-4-Di[β-D-galactopyranosyl-(1f4)-β-D-glucopyranosyl-(1f3)-
1-O-n-propyl-r-D-glucopyranuronamido]benzene 7. Removal of
the protecting groups from 32 (48 mg, 0.017 mmol) as described
for 6 gave, after semipreparative HPLC (gradient elution:
H2O-CH3CN, 99:1 to 96:4) and lyophilization, 7 (10 mg,
49%); [R]D þ2.19 (c 0.10, H2O); 1H NMR (D2O, 35 C, 600
MHz) δ 7.30 (s, 4H), 4.98 (d, J=3.6Hz, 2H), 4.74-4.73 (d, J=
7.8Hz, 2H), 4.47-4.40 (m, 6H), 4.15-4.13 (d, J=10.2Hz, 2H),
3.99-3.97 (dd, J = 2.4 Hz, J = 12.6 Hz, 2H), 3.95-3.93
(m, 4H), 3.82-3.75 (m, 8H), 3.74-3.71 (m, 2H), 3.69-3.63
(m, 10H), 3.62-3.61 (m, 2H), 3.55-3.52 (m and t overlapping,
J = 9.6 Hz, 4H), 3.41-3.38 (m, 2H), 1.66-1.60 (m, 4H),
0.92-0.90 (t, J = 7.8 Hz, 6H); 13C NMR (D2O, 150 MHz) δ
171.1, 137.0 (each C), 127.7, 103.2, 102.9, 98.7, 81.9, 78.7, 75.6,
75.1, 74.5, 73.5, 72.8, 71.8, 71.2, 70.9 (eachCH), 70.9 (CH2), 70.3
(CH2), 68.9 (CH), 61.3, 60.4, 42.8, 22.4 (each CH2), 10.2 (CH3);
HRMS (ESI) found 1220.4763 [MþH]þ, C50H80N2O32 requires
1220.4694.
Glycophane 8. Removal of the protecing groups from 31 (62
mg, 0.021 mmol) as described for formation of 6 gave 8, after
semipreparative HPLC (gradient elution: H2O-CH3CN, 99:1
to 96:4) and lyophilization, as a white solid (17 mg, 66%); [R]D
þ2.0 (c 0.17, H2O); 1H NMR (D2O, 35 C, 500 MHz) δ 7.30 (s,
4H), 4.93 (d, J = 2.0 Hz, 2H), 4.72-4.70 (d, J = 7 Hz, 2H),
4.51-4.48 (d, J = -14.0 Hz, 2H), 4.43-4.42 (d, J = 8.0 Hz,
2H), 4.28-4.25 (d, J=-14.0 Hz, 2H), 3.98-3.95 (m, 4H), 3.90
(d, J= 2.0 Hz, 2H), 3.85-3.83 (d, J= 9.0 Hz, 2H), 3.80-3.74
(m, 6H), 3.72-3.64 (m, 12H), 3.59-3.56 (m, 2H), 3.54-3.51 (m,
4H), 3.47-3.42 (m, 2H), 3.40-3.35 (m, 2H), 1.60-1.53 (m, 2H),
1.48-1.39 (m, 2H); 13C NMR (D2O, 125 MHz) δ 170.5, 138.2
(each C), 128.4, 103.2, 102.8, 99.2, 82.0, 78.6, 75.6, 75.1, 74.5,
73.4, 72.8, 71.7, 71.2, 70.9, 69.9 (each CH), 69.7 (CH2), 68.9
(CH), 61.3, 60.4, 42.7, 25.5 (each CH2); LRMS (ESI) 1189.2
[M - H]-, 593.6 [M - 2H]2-; HRMS (ESI) found 1190.4271
[M þ H]þ, C48H74N2O32 requires 1190.4225;
1,4-Di[1-(β-D-galactopyranosyl-(1f4)-β-D-glucopyranosyl)-
1,2,3-triazol-4-ylmethyloxy]benzene 9.Lactosyl azide 3323a (331
mg, 0.901 mmol) was dissolved in CH3CN-H2O (1:1, 4 mL),
then p-bispropargyloxybenzene11c 34 (84 mg, 0.451 mmol) and
sodium ascorbate (0.22mL of 0.4M) followed by CuSO4 3 5H2O
(0.22 mL of 0.2 M) were subsequently added and the mixture
was stirred for 12 h, after which it was diluted with H2O (15mL)
and extractd with EtOAc (2 5 mL). After lyophilization of the
aq solution the pale green powder (0.397 g) that was obtained
was added to pyridine-Ac2O (1:1, 10 mL) and the mixture was
stirred overnight. The volatile reagents were then removed
under diminished pressure and toluene (3  10 mL) was eva-
porated from the residue. Chromatography (EtOAc-cyclo-
hexane, gradient elution 1:1 to 2:1) gave the peracetate as an
off-white foam (0.517 g, 76% over two steps). Deacetylation of
this peracetate (0.314 g, 0.208 mmol) in MeOH-CH2Cl2 (10
mL, 4:1) as described for 6 gave, after lyophilization, 9 as a
brown solid (0.191 g, quantitative); [R]D þ38.5 (c 1.0, H2O); 1H
NMR (500MHz, D2O) δ 8.24 (s, 2H), 6.97 (s, 4H), 5.75 (d, J=
9.2 Hz, 2H, H-1), 5.16 (s, 4H), 4.49 (d, J= 7.8 Hz, 2H), 4.03 (t,
J = 9.1 Hz, 2H), 3.95-3.91 (m, 4H), 3.89-3.81 (m, 8H),
3.81-3.70 (m, 6H), 3.67 (dd, J =10.0 Hz, J = 3.4 Hz, 2H),
3.57 (dd, J = 9.9 Hz, J = 7.8 Hz, 2H); 13C NMR (125 MHz,
D2O) δ 152.5, 144.0 (each CH), 124.7 (C), 117.1, 103.2, 87.5,
78.0, 77.7, 75.6, 74.8, 72.8, 72.3, 71.2, 68.8 (each CH), 62.2, 61.3,
60.0 (each CH2); IR (KBr) 3502-3197 (br s), 1643, 1508, 1460,
1385, 1225, 1126, 1070 cm-1; LRMS (ESI) 943.1 [M þ Na]þ;
HRMS (ESI) found 921.3257 [MþH]þ, C36H53N6O22 requires
921.3213, and found 919.3021 [M-H]-, C36H53N6O22 requires
919.3056.
MolecularModeling.TheAMBER force field inMacromodel
and the GB/SA continuum25 for water were generally applied in
all calculations. Systematic conformational searches with the
SUMM method in Macromodel were carried out with 10 000
structures being generated starting from the initial model struc-
tures. Both glycosyl amide torsions (H1-C1-N-H) in the
divalent molecules 1, 3-5 were constrained to 171 with a force
constant of 2000 applied throughout the calculations. Each
conformer generated was minimized to convergence and all
structures within 12 kJ/mol of the global minimum for each
compound were retained and included in the analysis shown in
Figure 2. Conformational searches with 2 led to highly folded
low-energy structures which seemed unlikely to bind to lectins.
Thus stochastic molecular dynamics were also carried out for 2
beginning from an initial structure where the carbonyl group of
the terephthalamide residue was trans (OdC;CdO torsion
∼90). During the dynamics simulations a temperature of
300 K, time step of 1.5 fs, equilibration time of 1.0 ps, and
simulation time 2 nswere applied and500 structureswere selected
randomly over the duration of the simulation. The structures
obtained from the conformational searches and dynamics simu-
lations were analyzed in the same manner. In general the lactose
glycosidic torsionswere consistent in all structures generated.For
example, the average observed values for 1 from the conforma-
tional search were -72.0 ( 5.3 for φ and 132.1 ( 1.6 for ψ.
Lectins and Activity Assays. Extracts of dried mistletoe leaves
and of pellets of bacteria after recombinant production were the
sources for lectin purification by affinity chromatography on
lactosylated Sepharose 4B as crucial step.7g,k,26 Proteolytic
truncation by collagenase-dependent cleavage at the Tyr106/
Gly107 and Glu229/Ile230 peptide bonds in human galectin-3
was performed by a standard protocol.4a,8d Purity control by
one- and two-dimensional gel electrophoresis preceded biotiny-
lation under activity-preserving conditions and the following
activity controls by hemeagglutination with trypsin-treated and
glutaraldehyde-fixed rabbit erythrocytes as well as binding to
glycoproteins and human tumor cells.26a,27 Haemagglutination
(25) Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. J. Am.
Chem. Soc. 1990, 112, 6127–6129.
(26) (a) Gabius, H.-J.; Engelhardt, R.; Rehm, S.; Cramer, F. J. Natl.
Cancer Inst. 1984, 73, 1349–1357. (b) Gabius, H.-J.; Engelhardt, R.; Cramer,
F.; B€atge, R.; Nagel, G. A. Cancer Res. 1985, 45, 253–257. (c) Gabius, H.-J.
Anal. Biochem. 1990, 189, 91–94. (d) Gabius, H.-J.; Walzel, H.; Joshi, S. S.;
Kruip, J.; Kojima, S.; Gerke, V.; Kratzin, H.; Gabius, S. Anticancer Res.
1992, 12, 669–676. (e) Andre, S.; Kaltner, H.; Furuike, T.; Nishimura, S.-I.;
Gabius, H.-J. Bioconjugate Chem. 2004, 15, 87–98.
(27) (a) Gabius, H.-J.;Wosgien, B.; Hendrys,M.; Bardosi, A.Histochem-
istry 1991, 95, 269–277. (b) Purkrabkova, T.; Smetana, K., Jr.; Dvorankova,
B.; Holı´kova, Z.; B€ock, C.; Lensch, M.; Andre, S.; Pytlik, R.; Liu, F.-T.;
Klı´ma, J.; Smetana,K.;Motlı´k, J.; Gabius, H.-J.Biol. Cell 2003, 95, 535–545.
(c) Andre, S.; Pei, Z.; Siebert, H.-C.; Ramstr€om, O.; Gabius, H.-J. Bioorg.
Med. Chem. 2006, 14, 6314–6326. (d) Andre, S.; Maljaars, C. E. P.; Halkes,
K. M.; Gabius, H.-J.; Kamerling, J. P. Bioorg. Med. Chem. Lett. 2007, 17,
793–798.
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assays were performed with 2-fold serial dilutions of sugar in
triplicates with at least five independent test series. For studies in
vitro, cells of the human B lymphoblastoid line Croco II were
processed in aliquots of the same batch in triplicates and at least
three independent series with incubation of lectin-containing
solution at 4 C for 30min as labeling step andwith streptavidin-
R-phycoerythrin as reporter conjugate.27c,d Controls included
omission of the labeling step to determine the level of lectin-
independent background staining and application of noncog-
nate sugar to infer osmolarity effects. The solid-phase assaywith
spectrophotometric signal detection at 490 nm was performed
under optimized conditions as described previously.28 In detail,
the plastic surface of the microtiter plate wells was coated with
ligand by incubation of 50 μL of phosphate-buffered saline
(pH 7.2) containing the lectin-reactive glycoprotein (serum
amyloid P component: 0.5 μg; asialofetuin; 0.5 μg) at 4 C
overnight. Following blocking residual sites for protein adsorp-
tion by an incubation with 100 μLof buffer containing 1% (w/v)
carbohydrate-free bovine serum albumin for 1 h at 37 C and
washing, 50 μL of solution with biotinylated lectin was applied
at a concentration resulting in signal intensity within the linear
range (please see top part of Table 1 for details), and bound
lectin was detected by its biotin label using streptavidin-perox-
idase conjugate (0.5 μg/mL for 1 h at 37 C; Sigma, Munich,
Germany) and the chromogenic substrates o-phenylenediamine
(1 mg/mL) and H2O2 (1 μL/mL). Up to five series of indepen-
dent experiments were run in triplicates with standard devia-
tions not exceeding 17%.
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